Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis. by Angel, Zoe et al.
Appetite-regulating hormones—leptin, adiponectin and ghrelin— and the development of 
prostate cancer: a systematic review and exploratory meta-analysis 
 
Charlotte Zoe Angel 1,2 Isabel Iguacel1,3 Amy Mullee 1,4  Neela Guha1,5  Rachel Wasson1  Declan 
J. McKenna2 Marc J. Gunter1 Vitaly Smelov1  Inge Huybrechts1 
 
1 International Agency for Research on Cancer. World Health Organization, 150 cours 
Albert Thomas, 69372 Lyon CEDEX 08, France 
2 Biomedical Sciences Research Institute, Ulster University, Cromore Road, Coleraine, 
BT52 1SA, UK 
3 Department of Physiatry and Nursing, University of Zaragoza, Calle de Pedro Cerbuna, 
12, 50009 Zaragoza, Spain 
4 UCD School of Agriculture and Food Science, Institute of Food and Health, University 
College Dublin, Belﬁeld, Dublin 4, Ireland 
5 Ofﬁce of Environmental Health Hazard Assessment, California Environmental Protection 
Agency, Oakland, California, USA 
 
Corresponding author: Vitaly Smelov SmelovV@iarc.fr 
  
ABSTRACT 
 
Background Obesity has been proposed as a risk factor for prostate cancer (PCa). In obesity, serum 
levels of the appetite- regulating hormones—leptin, adiponectin, and ghrelin—become deregulated. 
Objective To explore whether serum levels of appetite-regulating hormones associate with the incidence 
of PCa, the incidence of advanced disease, or PCa-speciﬁc mortality. 
 
Methods PRISMA guidelines were followed. A systematic search for relevant articles published until 
March 2019 was performed using the databases PubMed, EMBASE, and Web of Science. 
Observational studies with data on serum levels of leptin, adiponectin, or ghrelin and PCa outcome were 
included. Meta-analysis was used to combine risk estimates. Meta- relative risks (mRRs) were 
calculated using random effects models. When available, raw data was pooled. Publication bias was 
assessed by funnel plot and Begg’s test. 
 
Results Thirty-ﬁve studies were eligible for inclusion. The qualitative analysis indicated that leptin was 
not consistently associated with any PCa outcome, although several cohorts reported decreased 
adiponectin levels in men who later developed advanced PCa. Based on the meta-analysis, there was 
no signiﬁcant effect of leptin on PCa incidence (mRR = 0.93 (95% CI 0.75–1.16), p = 0.52) or advanced 
PCa (mRR = 0.90 (95% CI 0.74–1.10), p = 0.30). There were insufﬁcient studies to estimate the mRR 
of PCa incidence for men with the highest levels of adiponectin. The combined risk of advanced PCa 
for men with the highest levels of adiponectin was reduced but did not reach signiﬁcance (mRR = 0.81 
(95% CI 0.61–1.08), p = 0.15). 
 
Conclusions The current evidence does not suggest an association between leptin and PCa outcome. 
However, there may be an inverse association between adiponectin and the incidence of advanced PCa 
that should be investigated by further studies. Serum ghrelin has not been largely investigated. 
 
 
 
 
  
  
INTRODUCTION 
 
Obesity affects numerous signalling networks that can inﬂuence carcinogenesis, including: insulin 
signalling, sex hormone signalling, and appetite-regulating hormones [1]. Therefore, obesity was 
proposed a risk factor for cancer, including prostate cancer (PCa), although the underlying mechanisms 
remain obscure in this context [2]. The Inter- national Agency for Research on Cancer (IARC) 
concluded that there was “limited evidence” for a positive association between body mass index (BMI) 
and risk of fatal cancer of the prostate, but no consistent association between BMI and incidence of 
total, non-aggressive (non-advanced), or aggressive (advanced) cancer of the prostate, from a review of 
about 50 prospective studies and more than 40 case-control studies [3]. However, the European Associa- 
tion of Urology (EAU) guidelines of 2018 cited the REDUCE study which indicated an increased risk 
of high- grade PCa associated with obesity [4]. Furthermore, the Continuous Update Project review 
conducted by the World Cancer Research Fund (WCRF) indicated that there was “strong evidence” that 
being overweight/obese increases the risk of "advanced" PCa [5]. To investigate these putative 
associations further, this review assessed the association between serum levels of appetite-regulating 
hormones and PCa, with a focus on advanced and fatal forms of the disease. 
 
Leptin and adiponectin are mainly produced and secreted by adipose cells, and are often referred to as 
"adipokines". Both act on the hypothalamus in the brain; leptin inhibits the sensation of hunger while 
adiponectin increases hunger. Ghrelin is mainly secreted by the stomach and gastro- intestinal tract and 
induces hunger. Adipokines regulate appetite, metabolism, and tissue expansion [6, 7]. Serum leptin 
levels increase with higher body fatness, while adi- ponectin and ghrelin levels may be reduced [8, 9]. 
In vitro studies indicated that leptin increased the proliferation of PCa cells by activating JAK/STAT, 
ERK, and PI3K/AKT/ mTOR pathways (Fig. 1) [7, 10]. Moreover, epidemiolo- gical studies suggested 
abnormally high serum leptin levels in patients with colon cancer, ovarian cancer, PCa, and breast 
cancer [6, 7]. Ghrelin similarly activates PI3K/AKT/ mTOR signalling, although its effect on PCa cells 
is unclear and seems to depend on the concentration administered to the cells [11]. One study found 
that ghrelin levels were lower in PCa patients [9], but the effect of this on PCa development is unclear, 
considering its interaction with growth-promoting signalling in vitro. Adiponectin may have growth-
suppressing effects in vitro: it activated AMPK and PKC with pro-apoptotic effects, and antagonised 
ERK signalling [7, 12]. Patients with liver cancer, breast cancer, and ovarian cancer had reduced 
adiponectin levels [6]. Furthermore, a meta-analysis concluded that the risk of PCa in men was 
associated with genetic polymorphisms in both the leptin and adiponectin receptors, suggesting that 
pros- tate cells are responsive to these hormones [13]. Therefore, adipokines may link obesity and PCa 
promotion. An association between serum levels and the incidence of PCa or of advanced PCa would 
support recommendations for men to maintain a healthy body weight to reduce their risk of PCa or to 
reduce its severity. Furthermore, it would suggest that these appetite-regulating hormones may have 
clinical value as biomarkers of PCa. However, the association between serum levels of these appetite-
regulating hormones has not been investigated by meta-analysis. Here, we performed a systematic 
review and meta-analysis of observational stu- dies with data on serum levels of leptin, adiponectin, 
and ghrelin. The outcomes analysed were: the incidence of PCa, the incidence of an advanced form of 
the disease, and PCa- speciﬁc mortality. 
 
  
SUBJECTS AND METHODS 
 
The review was conducted in accordance with the Preferred Reporting Items for Systematic reviews 
and Meta- Analyses (PRISMA) [14]. Prospero registration number: CRD42018105863. 
 
Data sources and search strategy 
 
PubMed/MEDLINE, EMBASE, Web of Science and The Cochrane Library (Central Trials) were 
searched, including MeSH terms (Supplementary appendix 1). The ﬁnal search was conducted on 14 
March 2019. 
 
Inclusion criteria 
 
Inclusion criteria: (1) The study design was deﬁned as case-control or nested case-control. (2) Cases 
were diagnosed by histological examination (biopsy or radical prostatectomy). (3) The cases had not 
received therapeutic intervention such as chemotherapy or radiotherapy for their PCa at the time of 
hormone measurement. (4) Results included comparison of serum leptin, adiponectin or ghrelin levels 
in cases and controls, or comparison of advanced and non-advanced cases. (5) The article was published 
as a full peer-reviewed report. Two reviewers performed screening independently at both stages. 
 
Evidence acquisition 
 
Data was extracted including the mean/median leptin levels (ng/μL) and adiponectin levels (μg/μL) 
with the standard deviation/standard error, odds ratios (OR) of the outcome with 95% conﬁdence 
intervals (CI), and details of any covariates adjusted for. Information about the study and cohort was 
extracted, including the population, study design, year, and country of recruitment. The outcomes 
investigated were: the incidence of PCa (all cases of PCa versus non-cancer controls), the incidence of 
advanced forms of the disease (advanced versus non-advanced cases), and PCa-speciﬁc mortality. The 
classiﬁcation system used to measure tumour advancement was recorded, such as by Tumour-Node-
Metastasis (TNM) clinical or pathological staging, or solely Gleason grading. An advanced clinical or 
pathological stage, and advanced Gleason grade tumour are hereafter referred to as “high-stage” and 
“high-grade” respectively. The authors’ deﬁnition of a “high-stage” or “high-grade” tumour was 
recorded. Details of control group were recorded, including number and type (i.e., healthy, benign 
prostatic hyperplasia (BPH), low-grade/low-stage cancer). The mean ages of the case and control 
groups, and race distribution were also recorded (Table 1, for full ver- sion see Supplementary Tables 
1–7). In one study there was a typographical error (conﬁrmed by the author): adiponectin levels were 
presented in ng/μL rather than μg/μL [15]. In another, leptin level was presented as pg/μL rather than 
ng/ μL (assumed an error but contact author did not reply) [16]. In another, adiponectin levels were 
presented in ng/μL rather than μg/μL but the author did not reply [17]. 
 
Evidence synthesis and statistical analysis 
 
Random effects models (Dersimonian and Laird method) were used to calculate summary risk estimates 
and 95% CIs [18]. Only ORs with age- and BMI-adjustment were included in the meta-analysis since 
age is a conﬁrmed risk factor for the disease [19] and BMI was considered a con- founding variable. In 
case-control studies, the mean/median differences in hormone levels between case and control group 
was analysed. In nested case-control studies, participants were considered as having “high” hormone 
levels, if they were in a top subset (tertile/quartile/quintile) and the OR of PCa for the top subsets from 
each cohort were combined to produce meta relative risk (mRR). The risk of high-stage and high-grade 
forms of the disease were assessed by comparing high-stage and high-grade cases compared to the low-
stage and low-grade cases. Addition- ally, high-stage and high-grade cancers were combined to assess 
the risk of “advanced” cancers, as has been previously reported in the IARC handbook of Cancer 
Prevention volume 16 [3]. Inconsistencies between the studies was assessed using the I2 statistic. An 
I2 value ranging from 0 to 25% was considered to represent low heterogeneity, from 26 to 50% 
moderate, and above 50% substantial het- erogeneity [20]. Publication bias was assessed by funnel plots 
using ﬁxed effects models and Begg’s tests [21]. Analyses were conducted in Review Manager 5.3 [22]. 
  
RESULTS 
Study characteristics 
 
Six hundred twenty four studies were obtained through literature review; 39 studies were included after 
the screening process (Fig. 2). Study characteristics are listed in brief in Table 1, with a full version in 
Supplementary Tables 1–7. There were 13 nested case-control studies (10 of which analysed leptin, 7 
analysed adiponectin) and 26 case-control studies (17 of which analysed leptin, 11 ana- lysed 
adiponectin and 2 analysed ghrelin). From all the studies combined, there were 7071 PCa patients in 
total. The nested case-control studies combined contained 4668 men who developed PCa, of which 
2867 with low-stage and 1425 with high-stage tumours, and 2058 with low-grade and 1502 with high-
grade tumours. The case-control studies combined contained 2403 men with PCa, of which 613 had a 
low-stage and 245 had a high-stage tumour, and 463 had a low-grade and 274 had a high-grade tumour. 
 
Systematic (qualitative) review 
 
Nested case-control and case-control studies were analysed separately. The results of studies with a 
case-control design, in which hormone levels in PCa cases versus controls were compared at the time 
of diagnosis, were considered a measure of “diagnostic” hormone levels. The results of nested case-
control studies, in which hormone levels in PCa cases versus controls were measured at the baseline of 
the cohort study and prior to the diagnosis of cancer, were considered as a measure of “pre-diagnostic” 
hormone levels. 
 
Leptin 
 
Six out of eight nested case-control studies reported no association between leptin and the onset of PCa 
[16, 23– 27],  nor  high-stage  [24,  25,  28],  nor  high-grade  PCa [16, 24, 25, 28]. Conversely, ten out 
of fourteen case-control studies reported an association with PCa incidence [29–37], two out of six with 
PCa stage [33, 35], and seven out of eight found an association with PCa grade  [29, 33, 35, 38, 39]. 
However, many had not adjusted for BMI [29–33, 35, 36]. Since leptin and adiponectin are derived 
from fat cells it is necessary to adjust for an anthropometric measurement such as BMI or waist-to-hip 
ratio, to analyse the effect independently of fat mass. Overall, despite a few exceptions there was no 
consistent association between leptin levels and PCa. 
 
Adiponectin 
 All four nested case-control studies that compared adiponectin level and the incidence of PCa found no 
association [16, 25, 27, 40] although results of a large cohort reported that participants that later 
developed PCa had lower levels of high-molecular weight (HMW) adiponectin [40] which is the most 
biologically active form [41]. One nested case-control study reported no association with tumour stage 
[28] and three reported no association with grade  [16, 28, 42]. One group combined the stage and grade 
score to classify tumours as “high-risk” and found no association [43]. The largest nested case-control 
analysis of high-stage PCa observed increased adiponectin levels inversely associated with incidence 
of advanced disease, in the over- weight and obese group (high-grade cases n = 311, low- grade controls 
n = 413, OR = 0.62 (95% CI, 0.42–0.90)) [28]. Another small analysis indicated an inverse association 
with high-grade PCa when diagnosed at radical prostatectomy (RP) (high-grade cases n = 9, low-grade 
controls n = 98; bottom quartile OR = 1.87, (95% CI, 0.82–4.23) [44]. However, another analysis at the 
time of RP reported that adiponectin was positively associated with high-stage but not high-grade PCa 
(high-stage OR = 1.14 (95% CI, 1.02–1.29)) in non-overweight men, whereas in overweight and obese 
men it was inversely associated with high-grade but not high-stage disease (high-grade OR = 0.94 (95% 
CI, 0.87–1.01) [45]. An analysis of a 25-year cohort (the Physicians’ Health Study) reported that 
increased pre-diagnostic adiponectin was strongly associated with decreased incidence of high-grade 
and lethal cancer (high-grade n = 121, low-grade n = 121; metastases or PCa-speciﬁc death n = 118; 
risk of high-grade RR = 0.49, (95% CI, 0.20–1.22); risk of lethal RR = 0.25, (95% CI, 0.07–0.87)) [25]. 
This was the only study identiﬁed to have analysed mortality and had a large number of advanced cases. 
  
As with leptin, case-control studies were more likely to report an association between adiponectin levels 
and PCa incidence than nested case-control studies. Most case-control studies reported lower 
adiponectin levels in total PCa patients than controls [15, 29, 32, 35, 46–50] with the exception of two 
[38, 39]. Similarly, most found reduced adiponectin levels in high-stage cases [29, 35, 46, 48] except 
for two [49, 51]. Three out of six found reduced adiponectin levels in high-grade cases [29, 35, 46] and 
three did not ﬁnd them signiﬁcantly different [38, 39, 48]. This difference between case-control and 
nested case-control results indicated that while pre-diagnostic adiponectin did not always predict PCa, 
it was frequently deregulated at the time of diagnosis. How- ever, since some of the case-control studies 
who reported an association had not matched case and control groups’ by BMI [29–31, 33, 35], it cannot 
be conﬁrmed that the association  is valid. 
 
Ghrelin 
 
Two small case-control studies had analysed serum levels of ghrelin; one reported higher mean levels 
in PCa patients [52], another reported that native ghrelin was unaltered in PCa patients, but the In1 
splice variant (a pathological splice variant) was increased in PCa at both the tissue and serum level 
[53]. 
 
Quantitative analysis 
 
A small number of nested case-control studies provided data suitable for inclusion in an exploratory 
meta-analysis of the published ORs, to assess the effect of pre-diagnostic hormone levels. There were 
too few case-control studies with published ORs to assess the effect of diagnostic hormone levels by 
meta-analysis. 
 
Leptin 
 
Men in the top subsets of leptin levels did not have a signiﬁcantly different risk of total PCa relative to 
those in the bottom subsets (Fig. 3a). Furthermore, the mRR of advanced PCa in men with high leptin 
was not signiﬁcantly different from non-advanced cases (Fig. 3b). This reﬂected the conclusion of the 
literature review of nested case-control studies, in which the majority of studies reported no signiﬁcant 
difference between the pre-diagnostic levels of leptin in PCa cases and controls, or advanced PCa cases 
compared to non-advanced. 
 
Adiponectin 
 
There were insufﬁcient studies that had provided BMI- adjusted ORs of the incidence of PCa, or of 
high-stage PCa, to calculate a mRR for either outcome. When the ORs of high-grade and high-stage 
PCa were combined to estimate the risk of advanced PCa in men with the highest subsets of adiponectin, 
the estimate for adiponectin levels in association with advanced PCa was mRR = 0.81 (0.61–1.08), p = 
0.15, I2 = 0% (Fig. 3d). Therefore, despite not reaching statistically signiﬁcant levels, this may suggest 
an inverse association between adiponectin levels and advanced PCa. The analysis of the Physicians’ 
Health Study [25] which reported a signiﬁcant inverse association between adiponectin and high-grade 
and lethal PCa, was excluded from the meta-analysis since they calculated Relative Risk (RR) rather 
than OR. We performed sensitivity analysis including and excluding this study, which did not affect the 
signiﬁcance of the mRR (mRR of advanced PCa in men with highest subset of adiponectin, including 
Li et al. [25],  mRR = 0.75 (0.54–1.06), p = 0.10, I2 = 27%). 
 Ghrelin 
 
Meta-analysis was not possible due to insufﬁcient studies. 
 
Analysis of standardised mean differences (SMD) and subgrouping 
 
For both leptin, pooling the SMD and subgrouping studies by mean age and BMI of participants (over 
and under 60 years, and over and under BMI of 25) did not affect mRR of PCa incidence (not shown). 
 
Publication bias 
 
There was no indication of publication bias in the studies utilised in the meta-analyses as indicated by 
funnel plot and Begg’s test (Supplementary Fig. 1). 
 
 
DISCUSSION 
 
Summary of evidence 
 
Overall, the evidence was very mixed, and due to study heterogeneity, only a small exploratory meta-
analysis could be performed. However, it seemed that while neither leptin nor adiponectin consistently 
associated with PCa incidence, and leptin did not consistently associate with advanced PCa, there was 
some suggestive evidence of an inverse association between adiponectin and advanced PCa. The mRR 
of advanced PCa was reduced for men with the highest pre- diagnostic levels of adiponectin, although 
this was not statistically signiﬁcant, and based on a small number of studies. This reﬂected the results 
of our qualitative review, which revealed nested case-control studies which had reported reduced 
adiponectin in men who were later diagnosed with advanced forms of PCa. Moreover, some case-
control studies reported reduced adiponectin levels in advanced PCa cases. Overall, there was some 
limited evidence of an inverse association between adiponectin and advanced PCa incidence, which 
could be investigated by further research. Interestingly, only one study had analysed PCa-speciﬁc 
mortality, reporting that pre-diagnostic adiponectin levels were predictive. Although stand alone, this 
cohort was large and further studies should investigate fatal PCa. Overall, these ﬁndings may implicate 
adiponectin as a hormone with anti-cancer effects. To ascertain causation, in vitro and in vivo work 
could further explore the effect of low adiponectin levels on PCa. Only two studies had analysed serum 
ghrelin levels, with opposing results, high- lighting a gap in the research. 
 
The IARC and WCRF came to differing conclusions regarding the association between obesity and 
advanced PCa, with the WCRF reporting a strong link between obesity and advanced PCa [3, 5]. This 
could be due to different inclusion criteria or qualitative scoring methods used by the different research 
groups when reviewing the evidence. Additionally, the WCRF evaluation focused on epidemiologic 
data whereas the IARC review also included mechanistic data from in vitro and in vivo studies and 
hence the overall evidence base was larger. Here we observed a lack of association between leptin and 
advanced PCa, and some limited evidence for an association between adiponectin and advanced PCa. 
However, it is important to note that a relationship between obesity and advanced PCa may hinge on 
other factors. Obesity affects many other circulating factors that in turn could affect PCa. For example, 
obesity is associated with increased fasting plasma triglycerides and LDL cholesterol, with lower HDL 
cholesterol, and with increased blood glucose, insulin and insulin-like growth factor 1 levels, as well as 
increased levels of free testosterone and estradiol [54, 55]. Moreover, obesity is considered a state of 
chronic, subclinical inﬂammation and is associated with increased systemic pro-inﬂammatory 
cytokines. Furthermore, men with obesity may have accompanying diabetes or high cholesterol, and 
may thus receive medications such as metformin or statins, which have been shown to affect PCa 
development [56, 57]. Thus the relationship between obesity and cancer risk and progression is highly 
complex and other factors beyond the scope of this review may play a role in PCa. 
 
Additionally, cancer cells may upregulate the appetite- regulating hormones’ pathways independently 
of circulating levels of the ligand (e.g. by overexpression or mutation of the receptor). In line with this 
hypothesis, genetic variants of the leptin receptor were shown to signiﬁcantly correlate with PCa risk 
[13]. Moreover, prostate tumours develop within a fatty tissue called periprostatic adipose tissue 
(PPAT), and increased PPAT has been correlated with PCa aggressiveness [58]. Potentially, the variant 
of leptin receptor or the concentration of local leptin levels are more important than systemic levels. 
Similarly, high molecular weight adiponectin may be more relevant than total levels. Hormaechea-
Agulla et al. reported that the In1-ghrelin variant was upregulated in PCa patients, as was observed in 
breast and endocrine tumours  [59–61].  Furthermore, other studies have reported that the ghrelin 
receptor and ghrelin-O-acetyltransferase (which converts ghrelin to its active form) were overexpressed 
in PCa cells and the serum of PCa patients [62, 63]. Therefore, downstream pathways may become 
dysregulated regardless of serum levels or the degree of adiposity. Nevertheless, this review suggests 
that neither leptin nor adiponectin would be sufﬁciently robust to act as markers of PCa incidence or 
prognosis. 
 
Study heterogeneity and limitations 
 
Several methodological discrepancies were observed. Authors had adjusted for various covariates 
including age, BMI, insulin signalling (i.e. c-peptide), smoking and testosterone. We suggest that future 
studies should adjust for body fat (e.g. BMI), and the conﬁrmed risk factors for PCa: age [19], 
race/ethnicity [64] and family history [65]. Furthermore, differences in the researchers’ tumour 
classiﬁcation systems (clinical staging, pathological staging at RP, or Gleason grading alone) produced 
heterogeneity. Reporting of tumour Gleason grade classiﬁcation was inconsistent, some studies classed 
Gleason grade 7 as high-grade whereas others classed it as intermediate-grade.  One would also expect 
variation in the apparent distribution of grade scores over time, due to revisions to the Gleason score 
system in 2005 and 2013 [66, 67]. Future approaches should use Grade Grouping; in which Gleason 
score 7 is split into its constituents (3 + 4 and 4 + 3) to characterise better the tumours with the most 
aggressive potential [68]. The TNM prognostic staging system has likewise been updated during the 
time in which the included studies were carried out. Although TNM stage ≥T3, locally advanced, or 
Stage III are typically considered “advanced/high-stage”, some cohorts had a different deﬁnition of high 
stage, such as ≥T2 and some included patients with metastatic PCa. This was a limitation of the review 
of advanced PCa, as studies designed with different deﬁnitions were compared. The small number of 
cohorts that were eligible for meta- analysis and had provided raw data was a limitation although 
heterogeneity was low. Another limitation was that, presumably, studies had utilised a single blood 
sample for the hormone measurement, as adipokines can be affected by time of day or even season. 
Furthermore, the use of a fasted blood sample was not always stated. Different sensitivities between the 
hormone-measuring assays that each study had used may have biased the pooling of the mean 
differences in hormone levels, although the results of pooled raw data reﬂected the mRR. In nested 
case-control studies, the participants had a hormone measurement taken at the study baseline but the 
length of time between baseline and diagnosis in each study was varied, which may have affected the 
mRR based on pre-diagnostic hormone levels. The review has several strengths; this is the ﬁrst meta- 
analysis of studies examining the effect of serum levels of 
  
leptin and adiponectin on PCa, advanced PCa, and lethal PCa. This review addressed whether they 
associate and therefore may have a contributory role PCa incidence or progression, and to evaluate their 
usefulness as a potential biomarker of disease. The search covered a particularly high number of 
publications, with no limits on geographical location or time-period. We concluded that leptin was not 
a robust predictor of PCa incidence nor advanced disease, although there may be an inverse association 
between adiponectin and advanced PCa that requires further attention. We considered that adjusting for 
BMI was essential since it is related to both the exposure (hormone) and outcome (PCa) and is thus a 
confounder. There were surprisingly few studies with data that were appropriate for combining by meta-
analysis, namely studies with BMI-matched groups and risk estimates of PCa by subset of hormone 
level. We believe this indicates the need for further research, with a particular focus on adiponectin and 
advanced PCa. We highlight the in vitro evidence for a potential role of ghrelin in PCa development 
and the lack of data on serum levels in PCa patients. We came to different conclusions than previous 
reviews that concluded that leptin levels were likely associated with high-grade PCa [10, 69]; we do not 
consider the evidence for this to be substantial. 
 
 
CONCLUSIONS 
 
The results suggested that serum levels of leptin were not associated with PCa nor advanced disease. 
However, the few studies that analysed adiponectin levels in PCa at the time of radical prostatectomy 
and PCa-speciﬁc mortality reported inverse associations, and our exploratory meta- analysis similarly 
suggested an inverse association. This implicates adiponectin as a potentially important hormone in 
mediating the relationship between obesity and PCa advancement. The effect of obesity on ghrelin 
levels and its relationship with prostate tumours has not been thoroughly investigated and may be 
important considering its emerging role in PCa signalling as shown by in vitro studies. 
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Table 1. Study characteristics of the articles in the systematic review.  
Study Study design 
(cohort, and 
duration) 
Hormone 
analysed 
PCa 
outcome 
analysed 
(and 
classificatio
n of 
Gleason 
grade 7) 
Gleason 7 
classed as 
intermediate 
grade or 
high-grade 
Country Detection 
Method 
Faste
d 
blood 
Cases N Cancer free 
controls N 
(or 
otherwise) 
Arisan et al 
2009  
Case-control Leptin, 
adiponectin 
Incidence, 
risk of high-
stage, risk 
of high-
grade 
Intermediate Turkey ELISA Yes 50 (of which 
18 advanced 
stage, and 
either 8 
(Table 1 
data) or 24 
or 8 (Table 2 
data) high-
grade) 
50 (and 32 
organ-
confined, and 
either 10 
(Table 1 
data) or 11 
(Table 2 
data) low-
grade 
tumours) 
Baillargeon 
et al 2006  
Nested case-
control (San 
Antonio Center 
for Biomarkers 
of Risk of 
Prostate Cancer 
(SABOR) 
cohort, March 
2001 - Aug 
2005) 
Leptin, 
adiponectin 
Incidence, 
risk of high-
grade 
High USA LabMAP Not 
stated 
125 (of 
which 40 
high-grade) 
125 (and 85 
low-grade 
tumours) 
Burton et al 
2013  
Nested case-
control 
(ProtecT 
cohort, 2001-
2009) 
Leptin, 
adiponectin 
Risk of 
high-stage, 
risk of high-
grade 
High UK ELISA No 307 (of 
which 311 
locally 
advanced, 
307 high-
grade) 
416 (and 413 
low-stage and 
416 low-
grade 
tumours) 
Capoun et 
al 2015  
Case-control Leptin Incidence High Czech 
Republic 
ELISA Yes 167 (of 
which 10 
high-grade) 
206 (and 119 
low-grade 
tumours) 
Chang et al 
2001  
Case-control Leptin Risk of 
high-
volume 
localised 
tumour 
Measured 
tumour 
volume 
USA RIA Not 
stated 
151 (all 
high-
volume) 
48 (all low-
volume) 
Duarte et al 
2018  
Case-control Leptin Incidence Not stated Portugal ECLIA Not 
stated 
103 78 
Fontana et 
al 2011  
Case-control Leptin, 
adiponectin 
Incidence, 
risk of high-
grade 
Intermediate Argentin
a 
ELISA 
 
Not 
stated 
35 (of which 
9 high-
grade) 
35 (and 12 
low-grade 
and 14 
intermediate-
grade 
tumours) 
Fowke et al 
2013  
Nested case-
control 
(Nashville 
Men’s Health 
Study, 2003-
Dec 2008) 
 
Leptin, 
adiponectin 
Risk of 
high-grade 
High USA RIA Not 
stated 
100 (high-
grade) 
100 (all low-
grade) 
Freedland et 
al 2005  
Case-control Leptin Risk of 
stage pT3 
and high-
grade at RP 
High USA ELISA Not 
stated 
1 (pT3a), 78 
(high-grade) 
224 (non-
pT3a), 158 
(low-grade) 
Freedland et 
al 2005   
Case-control Adiponecti
n 
Risk of 
stage pT3 
and high-
grade at RP 
High USA ELISA Not 
stated 
1 (pT3a), 78 
(high-grade) 
224 (non-
pT3a), 158 
(low-grade) 
 Fryczkows
ki et al 2018  
Case-control Leptin Incidence Not stated Poland ELISA Not 
stated 
40 (all 
Gleason 
grade 6-7) 
40 BPH 
Gade-
Andavolu et 
al 2006  
Case-control Leptin Incidence Not stated USA RIA Not 
stated 
69 137 
Goktas et al 
2005  
Case-control Adiponecti
n 
Risk of 
high-stage, 
risk of high-
grade 
Intermediate Turkey 
 
RIA Yes 30 (of which 
16 
(advanced 
stage 
≥T3N0M0, 9 
high-grade) 
36 (and 8 
low-grade 
and 13 
intermediate-
grade 
tumours) 
Grosman et 
al 2010  
Case-control Adiponecti
n 
Incidence High Argentin
a 
RIA Yes 25 (of which 
10 high-
grade) 
25  
Grosman et 
al 2016  
Case-control Leptin Incidence High Argentin
a 
RIA Yes 70 (of which 
12 poorly 
differentiate
d) 
70 (58 
moderately 
differentiated 
tumours) 
Hormaeche
a-Agulla et 
al 2017  
Case-control Ghrelin Incidence Gleason -7 
and Gleason 
>7 
Spain ELISA 
(total 
ghrelin), 
RIA (In1 
ghrelin) 
Not 
stated 
20 (of which 
8 Gleason 6, 
9 Gleason 7, 
7 Gleason 8, 
6 Gleason 9) 
30 
Housa et al 
2007  
Case-control Adiponecti
n 
Incidence, 
risk of high-
stage 
High Czech 
Republic 
ELISA Yes 43 (of which 
26 pT3 
locally 
advanced, 
not 
metastasised
, 7 high-
grade) 
25 BPH (17 
pT2 and 19 
low-grade 
tumours) 
Hsing et al 
2001  
Nested case-
control 
(Shanghai 
Cancer Institute 
and 28 
collaborating 
hospitals, 1993-
1995) 
Leptin Incidence "Advanced" 
and "poorly 
differentiated
"  
China 
 
RIA Yes 128 (of 
which 
approximatel
y 66% high-
stage, >60% 
moderately 
or poorly 
differentiate
d) 
306 
(approximate
ly 33% low-
stage, and 
<40% low-
grade 
tumours) 
Ikeda et al 
2015  
Case-control Adiponecti
n 
Incidence, 
risk of high-
stage 
Measured 
Clinical T 
stage and 
D’Amico  
Japan Latex 
particle-
enhanced 
turbidimetri
c 
immunoassa
y 
Not 
stated 
24 (of which 
4 T2c (1 
T2a, 1 T2b, 
2 T2c), 8 
D’Amico 
high-risk) 
2,817 (20 
T1c and 16 
low or 
medium 
D’Amico risk 
tumours) 
Kang et al 
2018  
Case-control Leptin, 
adiponectin 
Risk of 
high-grade 
at RP in 
healthy 
versus 
obese men 
Intermediate South 
Korea 
RIA (for 
leptin), 
ELISA (for 
adiponectin) 
Not 
stated 
62 (of which 
1 high-stage 
(≥pT3)) 
24 low-stage 
(≤T2) 
Lagiou et al 
1998  
Case-control Leptin Incidence Not stated Greece RIA Not 
stated 
43 (of which 
5 metastatic 
at time of 
diagnosis) 
48 
Lai et al 
2014  
Nested case-
control (Health 
Professionals 
Follow-up 
Study, 1993-
2004) 
Leptin Incidence High USA ELISA No 1314 (of 
which 156 
high-stage, 
477 high-
grade) 
1314 (1064 
low-stage, 
736 low-
grade 
tumours) 
Li et al 
2010  
Nested case-
control 
(Physician's 
Health Study, 
1982-2000 +10 
year follow up 
on cases) 
Adiponecti
n, leptin 
Incidence, 
risk of high-
stage, risk 
of high-
grade 
Intermediate USA RIA Not 
stated 
654 (of 
which 121 
high-stage 
and 124 
high-grade 
used in 
analysis) 
644 (121 
low-stage and 
124 low-
grade 
tumours) 
Malendowi
cz et al 
2009  
Case-control Ghrelin Incidence Measured 
Localised 
and 
metastasised 
Poland RIA Yes 18 (of which 
13 low-
stage, 5 
metastasised
) 
16 
Medina et 
al 2013  
Nested case-
control 
(SABOR 
cohort, 2001 - 
2013) 
Adiponecti
n 
Incidence, 
risk of high-
grade 
High USA ELISA Not 
stated 
228 (of 
which 72 
high-grade 
239 (and 140 
low grade 
tumours) 
Michalakis 
et al 2007  
Case-control Adiponecti
n 
Incidence Intermediate Greece RIA Yes 75 (of which 
13 stage III 
and 5 stage 
IV, and 19 
high-grade) 
150 (and 8 
stage I, 45 
stage II, and 
5 low-grade 
and 48 
intermediate 
grade 
tumours) 
Michalakis 
et al 2015  
Case-control Adiponecti
n 
Incidence Measured 
localised and 
metastasised 
Greece RIA Yes 75 (of which 
5 
metastasised
) 
150 
Nishimura 
et al 2012  
Case-control Leptin, 
adiponectin 
Incidence Not stated Japan ELISA Not 
stated 
54 70 BPH 
Saǧlam et al 
2003  
Case-control Leptin Incidence, 
risk of high-
stage, risk 
of high-
grade 
Intermediate Turkey RIA Yes 21 (of which 
10 locally 
advanced 
and 
T3N0M0, 7 
high-grade) 
50 (and 11 
organ-
confined, 5 
low-grade 
and 9 
intermediate 
grade 
tumours) 
Serretta et 
al 2018  
Case-control Leptin, 
adipopnecti
n 
Risk of 
Gleason 
score 4 or 5 
High Not 
stated 
ELISA Not 
stated 
146 (of 
which 68 
Gleason 
score 4 or 5) 
81 Gleason 
score 3 
Sher et al 
2008  
Nested case-
control (Dana 
Farber Cancer 
Institute, Nov 
2001 - Dec 
2005) 
Adiponecti
n 
Risk of 
high-grade  
Intermediate USA ELISA Not 
stated 
539  (of 
which 199 
high-stage (1 
pTx, 176 
pT2, 19 
pT3) and 9 
high-grade) 
98 low-stage 
(67 cTx, 355 
cT1, 105 
cT2, 5 cT3) 
98 low-grade 
and 92 low-
grade) 
Siemińska 
et al 2018  
Case-control Leptin, 
adiponectin 
Incidence, 
risk of high-
grade 
Intermediate Poland ELISA Yes 74 (of which 
22 high-
grade) 
66 BPH (and 
24 low-grade 
tumours) 
Singh et al 
2010  
Case-control Leptin Incidence High India 
 
ELISA 
 
Not 
stated 
30 (of which 
12 locally 
advanced, 14 
metastasised 
to bone, 7 
high-grade) 
30 (and 4 
localised, 23 
low-grade 
tumours) 
Stattin et al 
2000  
Nested case-
control (WHO 
Monica 1986-
1994, 
Vasterbotten 
Intervention 
Program (VIP) 
Jan 1985 - 
March 1999) 
Leptin Incidence “highly, 
intermediatel
y, or poorly 
differentiated
” 
Sweden RIA Yes 149 (of 
which 16 
locally 
advanced, 20 
metastasis (6 
to lymph 
node, 14 to 
bone) 
298 (and 113 
low-stage and 
130 low-
grade 
tumours) 
Stattin et al 
2003  
Nested case-
control (Janus 
project 1973-
1997) 
Leptin Incidence Not stated Norway RIA Not 
stated 
200 397 
Stevens et 
al 2014  
Nested case-
control (CPS II 
Nutrition 
cohort, 1992-
2014) 
Adiponecti
n 
Risk of 
high-stage 
Aggressive 
defined as 
Gleason ≥7, 
High-risk 
defined as 
Gleason ≥8 
USA ELISA Not 
stated 
69 (of which 
44 stage T3, 
25 stage T4, 
108 Gleason 
7, 73 
Gleason 8, 
46 Gleason 
9-10). 
194 (and 194 
organ 
confined, 27 
Gleason 6 or 
7 tumours) 
Stocks et al 
2007 
Nested case-
control 
(Vasterbotten 
Intervention 
Project 1985- 
2004) 
Leptin Incidence, 
risk of high-
stage, risk 
of high-
grade 
Intermediate Sweden RIA Yes 392 (of 
which 12 
stage N1 
lymph node 
metastasis, 
232 stage Nx 
no lymph 
node 
extirpation; 
37 with bone 
metastasis; 
84 Mx no 
bone scan, 
51 high-
grade) 
392 (and 20 
stage T1a,b;  
167 stage 
T1c; 146 
stage 
localised T2; 
55 stage non-
localised T3, 
T4, 146 low-
grade, 195 
intermediate-
grade) 
Tewari et al 
2013  
Case-control Leptin, 
adiponectin 
Incidence, 
risk of high-
stage, risk 
of high-
grade 
Not stated India Not stated Not 
stated 
95 (of which 
31 Stage IV, 
62 high-
grade) 
95 BPH (and 
64 Stage III, 
33 low-
grade) 
Touvier et 
al 2012  
Nested case-
control 
(Supplémentati
Leptin, 
adiponectin 
Incidence Not stated France  ELISA Yes 156  312 
on en 
Vitamines et 
Minéraux 
AntioXydants 
(SU. VI. 
MAX), 1994-
2007) 
 
ELISA: enzyme-linked immunoassay, RIA: radio-immunoassay, LabMAP: Luminex LabMAPTM system, BPH: 
benign prostatic hyperplasia, n/a: non-applicable, ECLIA: electrochemiluminescent assay.  
FIGURE LEGENDS 
 
Fig. 1 Schematic overview of the interaction between appetite- regulating hormones and the prostatic 
epithelial cell (see also ref.  [1]). Arrows indicate direction of regulation, barred lines indicate inhibition. 
Arrows’ thickness indicates serum concentration (thick = high, thin = low). Dotted lines = indirect 
action, solid lines = direct action. Black arrows = leptin, blue arrows = adiponectin, green arrows = 
ghrelin. Leptin is secreted proportionally by adipocytes and adiponectin inverse proportionally, so that 
when adipose tissue increases, circulating leptin is increased and circulating adiponectin decreased. 
Ghrelin is secreted by the stomach. The hormones act on the hypothalamus (red spot) to modulate 
appetite, which can in turn affect appetite. The effect of obesity on the level of ghrelin remains poorly 
understood. In prostate cells, receptors responsive to acetylated ghrelin (growth hormone secretagogue 
receptor (GHSR)), adiponectin receptor (AdipoR), and leptin receptor (LepR) are expressed. These 
activate pathways that are involved in regulation of proliferation, migration, angiogenesis (e.g. growth 
promoting JAK/STAT/ERK or PI3K/AKT/mTOR or growth-inhibiting AMPK/PPA2) and apoptosis 
(AMPK/PKC and Caspase-3). The pathways are interlinked and the hormones regulate one another [7] 
 
Fig. 2 Flow chart depicting the systematic screening process. Adapted From: Moher D, Liberati A, 
Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097. For more information, visit www.prisma-statement.org. 
 
Fig. 3 Meta-analysis of BMI-adjusted models from nested case- controls. a The mRR of PCa incidence 
in men with highest subset of leptin. Baillargeon et al: 125 PCa cases, 125 healthy controls, Hsing et al: 
128 PCa cases, 306 healthy controls; Lai et al: 1,314 PCa cases, 1,314 healthy controls; Stattin et al: 
146 PCa cases, 298 healthy controls; Touvier et al: 156 PCa cases, 312 healthy controls. Total: 1,872 
PCa cases, 2,355 healthy controls. b The mRR of advanced PCa in men with highest subset of leptin. 
Baillargeon et al (grade): 40 high- grade cases, 85 low-grade cases; Burton et al (grade): 307 high-grade 
cases, 416 low-grade cases; Burton et al (stage) 311 high-stage cases, 413 low-stage cases; Lai et al. 
(grade): 477 high-grade cases, 736 low- grade cases; Lai et al. (stage): 156 high-stage cases, 1,064 low-
stage cases. Total: 1,291 advanced cases, 2,714 non-advanced cases. c The mRR of high-grade PCa in 
men with highest subset of adiponectin. Baillargeon et al:  40 high-grade cases, 85 low-grade cases;  
Burton  et al.: 307 high-grade cases, 416 low-grade cases; Sher et al: 9 high- grade cases, 92 low-grade 
cases. Total: 356 high-grade cases, 593 low- grade cases. d The mRR of advanced PCa in men with 
highest subset of adiponectin. Baillargeon et al. (grade): 40 high-grade cases, 85 low- grade cases; 
Burton et al (stage): 311 high-stage cases, 413 low-stage cases; Burton et al. (grade): 307 high-stage 
cases, 416 low-stage cases; Sher et al. (grade): 9 high-grade cases, 92 low-grade cases; Stevens  et al. 
(stage): 69 high-stage cases, 194 low-stage cases. Total:736 advanced cases, 1,200 non-advanced cases 
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Articles identified through reference mining  
(n = 2) 
Articles after duplicates removed  
(n = 624) 
Title and Abstracts screened  
(n = 624) 
Articles excluded  
(n = 550) 
Full-texts screened 
(n = 74) 
Articles excluded (n = 35) 
Patients had received treatment (n=11) 
(1)(2)(3)(4)(5) 
(6)(7)(8)(9)(10)(11) 
Insufficient data provided (n=1) 
(12) 
Not a full article (n=6) (e.g. poster, 
conference abstract)  
(13)(14)(15)(16)(17)(18) 
No access to full text (n=1) neither via our 
institutions nor by contacting first author  
(19) 
Otherwise unrelated (n=16) 
(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(3
1)(32)(33)(34)(35) 
 
 
 
Studies included in qualitative 
synthesis (systematic review)  
(n = 39) 
Studies included in quantitative 
synthesis (meta-analysis) 
(n =  8) 
(63)(64)(65)(66)(67)(68)(69)(70) 
Articles identified through database searching 
PubMed/MEDLINE (n = 301)  
EMBASE (n = 254) 
Web of Science (n = 440) 
The Cochrane Library Central Trials (n = 17) 
 
Articles excluded (n = 31) 
Compared mean/median cases vs control levels with no OR 
provided: 
(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(5
2) 
Subsetted hormone levels but was case-control study 
(insufficient in number for combining): 
(53)(54)(55)(56)(57)(58)(59)(60) 
Nested case-control, but hormone levels not subsetted (e.g. 
dichotomised, or OR of incremental increase provided): (61) 
Calculated Relative Risk instead of OR: (62) 
BMI not adjusted: (63) 
Data not provided, author did not reply to request: (64) 
Analysed ghrelin (insufficient in number for combining): (65)(66) 
 
A) The mRR of PCa incidence in men with highest subset of leptin  
 
 
B) The mRR of advanced PCa in men with highest subset of leptin  
 
C) The mRR of high-grade PCa in men with highest subset of adiponectin  
 
 
D) The mRR of advanced PCa in men with highest subset of adiponectin  
 
  
SUPPLEMENTARY FIGURES AND TABLES 
 
LEGENDS 
Supplementary Figure 1. Publication bias assessment of the studies included in the meta-analyses of 
BMI-adjusted models from nested case-controls. A) ORs of the PCa incidence in men with highest 
subset leptin. B) ORs of advanced PCa in men with highest subset leptin. C) ORs of high-grade PCa 
in men with highest subset adiponectin. D) ORs of advanced PCa in men with highest subset 
adiponectin.   
 
Supplementary Table 1. Extracted data from studies analysing serum leptin levels and the 
incidence of PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of the mean; 
OR: Odds ratio; RR: risk ratio; BMI: body mass index; T: tertile; Q: quartile or quintile; PSA: prostate 
specific antigen; BPH: Benign prostate hyperplasia; WHR: waist-to-hip ratio, IGF-1: insulin-like 
growth factor-1; SHGB: sex hormone-binding globulin; SU.VI.MAX: The Supplementation en 
Vitamines et Mineraux Antioxydants study.  
 
Supplementary Table 2. Extracted data from studies analysing serum leptin levels and the 
incidence of high-stage PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of 
the mean; OR: Odds ratio; RR: risk ratio; BMI: body mass index; T: tertile; Q: quartile or quintile; 
PSA: prostate specific antigen. *In the methods section it states that fasting was stratified and adjusted 
for although the stratified table is not provided in the results. 
 
Supplementary Table 3. Extracted data from studies analysing serum leptin levels and the 
incidence of high-grade PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error 
of the mean; OR: Odds ratio; RR: risk ratio; BMI: body mass index; T: tertile; Q: quartile or quintile; 
PSA: prostate specific antigen. *As presented in tables 1 and 2, respectively. *In the methods section 
it states that fasting was stratified and adjusted for although the stratified table is not provided in the 
results. 
 
Supplementary Table 4. Extracted data from studies analysing serum adiponectin levels and the 
incidence of PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of the mean; 
OR: Odds ratio; RR: risk ratio; BMI: body mass index; T: tertile; Q: quartile or quintile; PSA: prostate 
specific antigen; BPH: Benign prostate hyperplasia; WHR: waist-to-hip ratio, IGF-1: insulin-like 
growth factor-1; SHGB: sex hormone-binding globulin; SU.VI.MAX: The Supplementation en 
Vitamines et Mineraux Antioxydants study. *Human adiponectin latex kit; Otsuka Pharmaceutical 
Co., Tokyo, Japan. 
 
Supplementary Table 5. Extracted data from studies analysing serum adiponectin levels and the 
incidence of high-stage PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of 
the mean; OR: Odds ratio; BMI: body mass index; RR: risk ratio; HR: Hazard ratio; CDR: cancer 
detection rate; T: tertile; Q: quartile or quintile. 
 
Supplementary Table 6. Extracted data from studies analysing serum adiponectin levels and the 
incidence of high-grade PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error 
of the mean; OR: Odds ratio; BMI: body mass index; RR: risk ratio; T: tertile; Q: quartile or quintile; 
RP: radical prostatectomy. *As presented in tables 1 and 2, respectively. 
 
Supplementary Table 7. Extracted data from studies analysing serum ghrelin levels and the 
incidence PCa. C-C: cases vs. controls; SEM: standard error of the mean, In1 ghrelin: oncogenic 
ghrelin splice variant with retention of intron 1, IQR: interquartile range.  
 
Supplementary Figure 1.  
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Study Coun
try 
Study 
design 
Exposure 
category 
Detection 
Method 
Exposure metric 
(ng/ml) 
Risk estimate PInteraction/PTren
d 
Matched factors/ 
Covariates 
Fasted 
blood 
Case
s N 
Cancer
-free 
control
s N 
Arisan et al 
2009(1) 
Turke
y 
Case-
control 
Comparison 
of C-C mean 
levels 
ELISA Controls 12.98[no 
SD/SEM], Cases not 
provided. P-value not 
provided. 
Not provided   Age, BMI Yes 50 50 
Baillargeon et 
al 2006(2) 
USA Nested 
case-
control 
Tertiles LabMAP T1: range not provided Reference     Not 
stated 
125 125 
     Tertiles  T2: range not provided OR=0.50(0.26-
0.97) 
  Age, Race/ethnicity      
     Tertiles  T3: range not provided OR=0.77(0.43-
1.37) 
P=0.57 Age, Race/ethnicity      
     Tertiles  T2: range not provided OR=0.51(0.19-
1.27) 
  Age, Race/ethnicity, 
BMI 
     
     Tertiles  T3: range not provided OR=1.28(0.57-
2.88) 
P=0.35 Age, Race/ethnicity, 
BMI 
     
     Tertiles  Highest vs.  lowest tertile 
(range not provided) 
OR=0.77(0.28-
1.37) 
P=0.57 Age, Race/ethnicity      
     Tertiles  Highest vs.  lowest tertile 
(range not provided) 
OR=1.28(0.57-
2.88) 
P=0.35 Age, Race/ethnicity, 
BMI 
     
   Comparison 
of C-C mean 
levels 
 Controls mean 11.1pg/ml 
(SD± 11.7pg/ml) . 
Cases mean 8.62pg/ml 
(SD± 7.4pg/ml) (p=0.09, 
(McNemar’s test/ paired t 
test, α=0.05)) 
      
Capoun et al 
2015(3) 
Czech 
Repub
lic 
Case-
control 
Comparison 
of C-C mean 
levels 
ELISA Controls: Mean 7.64 
(SD±6.44). Cases: Mean 
7.84 (SD±7.35). P=0.9001 
Not provided   Age, BMI Yes 167 206 
Duarte et al 
2018 (4) 
Portug
al 
Case-
control 
Comparison 
of C-C mean 
levels 
 Controls: Mean 
11.93 (± 19.45). Cases: 
Mean 15.26 (± 23.60). P 
value not provided. 
Not provided  None Not 
stated 
103 78 
Fontana et al 
2011(5) 
Argent
ina 
Case-
control 
Comparison 
of C-C mean 
levels 
ELISA 
 
Controls: Mean 5.96 (SEM 
not provided). Cases: 
Mean 4.89 (SEM not 
provided). P-value not 
provided 
Not provided  Age, BMI Not 
stated 
35 35 
Fryczkowski 
et al 2018 (6) 
Poland Case-
control 
Comparison 
of C-C mean 
levels 
ELSIA Controls: Mean 11.2(6.0–
16.0), Cases: Mean 15.7 
(8.2–26.8), p=0.02 
OR=1.053(1.009-
1.098) 
p=0.04 Age, BMI Not 
stated 
40 40 BPH 
Gade-
Andavolu et 
al 2006(7) 
USA Case-
control 
Comparison 
of C-C mean 
levels 
RIA Controls: Mean 7.88 
(SEM± 1.08). Cases: 
Not provided   Age Not 
stated 
69 137 
Mean 14.7 (SEM± 1.38). 
P-value not provided. 
Grosman et al 
2016(8) 
Argent
ina 
Case-
control 
Comparison 
of C-C median 
levels 
RIA Controls: Median 
4.8(Range 1.1–12.3). 
Cases: Median 6.5(Range 
1.3–28.0). p<0.01 
Not provided   Age, BMI Yes 70 70 
Hsing et al 
2001(9) 
China 
 
Nested 
case-
control 
Per tertile RIA T1: <2.30 Reference     Yes 128 306 
     Per tertile  T2: 2.31–4.04 OR=0.97(0.56-
1.69) 
  Age      
     Per tertile  T3: >4.04 OR=1.78(1.07-
2.95) 
P=0.02 Age      
     Per tertile  T2: 2.31–4.04 OR=0.67(0.36-
1.27) 
  Age, Education, BMI, 
WHR 
     
     Per tertile  T3: >4.04 OR=1.10(0.59-
2.07) 
P=0.66 Age, Education, BMI, 
WHR 
     
   Per tertile  T2: 2.31–4.04 OR=0.60(0.38-
1.15) 
  Age, Education, BMI, 
WHR, Insulin, IGF-1 
   
   Per tertile  T3: >4.04 OR=0.80(0.52-
1.90) 
P=0.95 Age, Education, BMI, 
WHR, Insulin, IGF-1 
   
Lagiou et al 
1998(10) 
Greec
e 
Case-
control 
Incremental 
OR 
RIA Per 4ng/ml increase OR=1.02   Age Not 
stated 
43 48 
     Incremental 
OR 
 Per 4ng/ml increase OR=0.97. 
 
Age, height, Years of 
Schooling 
     
   Incremental 
OR 
 Per 4ng/ml increase OR=1.02  Age, height, Years of 
Schooling, BMI 
   
Lai et al 
2014(11) 
USA Nested 
case-
control 
Incremental ELISA Per quartile increase OR=0.94(0.88–
1.01) 
  Age, PSA, Year, Time 
of day, Season 
No  1314 
 
 
 
Incremental  Per quartile increase OR=0.93(0.86–
1.02) 
 
Age, PSA, Year, Time 
of day, Season, BMI, 
history of diabetes 
 
  
   Per quartile  Q1: cut-off  not provided       
     Per quartile  Q2: cut-off s of 4 batches 
8.72, 8.63, 8.39, 4.42 
OR=0.97(0.78–
1.20) 
  Age, PSA, Year, Time 
of day, Season 
     
     Per quartile  Q3: cut-off s of 4 batches 
15.34, 14.45, 13.95, 6.83 
OR=0.85(0.68–
1.06) 
  Age, PSA, Year, Time 
of day, Season 
     
     Per quartile  Q4: cut-off s of 4 batches 
24.05, 25.24, 21.82, 11.41 
OR=0.86(0.69–
1.06) 
 Not provided Age, PSA, Year, Time 
of day, Season 
     
 
 
 
Per quartile  Q2: cut-off s of 4 batches 
8.72, 8.63, 8.39, 4.42 
OR=0.96(0.78–
1.20) 
 
Age, PSA, Year, Time 
of day, Season, BMI, 
history of diabetes 
 
 
  
   Per quartile  Q3: cut-off s of 4 batches 
15.34, 14.45, 13.95, 6.83 
OR=0.84(0.67–
1.06) 
 Age, PSA, Year, Time 
of day, Season, BMI, 
history of diabetes 
   
   Per quartile  Q4: cut-off s of 4 batches 
24.05, 25.24, 21.82, 11.41 
OR=0.84(0.64–
1.10) 
Not provided Age, PSA, Year, Time 
of day, Season, BMI, 
history of diabetes 
   
Li et al 
2010(12) 
USA Nested 
case-
control 
Per quintile RIA Q1: 2.3(0.8–3.2) Reference     Not 
stated 
654 644 
     Per quintile  Q2: 3.9(3.3–4.6) RR=1.06(0.74–
1.52) 
  Age    
     Per quintile  Q3: 5.5(4.7–6.5) RR=1.07(0.75–
1.54), 
  Age      
     Per quintile  Q4: 8.0(6.6–10.0) RR=1.09(0.76–
1.56) 
  Age      
     Per quintile  Q5: 14.1(10.1–50.6) RR=1.05(0.73–
1.51) 
p=0.9 Age      
     Per quintile  Q2: 3.9(3.3–4.6) RR=1.00(0.67–
1.49) 
  Age, BMI, c-peptide      
     Per quintile  Q3: 5.5(4.7–6.5) RR=1.07(0.70–
1.64) 
  Age, BMI, c-peptide      
     Per quintile  Q4: 8.0(6.6–10.0) RR=1.10(0.71–
1.71) 
  Age, BMI, c-peptide      
     Per quintile  Q5: 14.1(10.1–50.6) RR=1.06(0.65–
1.72) 
p=0.8 Age, BMI, c-peptide      
Nishimura et 
al 2012(13) 
Japan Case-
control 
Per quartile ELISA Q1: range not provided Reference     Not 
stated 
54  70 BPH 
     Per quartile  Q2: range not provided OR=1.00(0.36-
2.77) 
  Age    
 
     Per quartile  Q3: range not provided OR=1.15(0.40-
3.30) 
  Age      
     Per quartile  Q4: range not provided OR=2.83(1.00-
8.43) 
Wald p=0.17. Age      
     Highest vs.  
lowest 
 Q1-4 vs.  4 OR=2.72(1.14-
6.81) 
Wald p=0.027 Age      
     Per quartile  Q2: range not provided OR=0.87(0.31-
2.45) 
  BMI      
     Per quartile  Q3: range not provided OR=1.07(0.38-
3.00) 
  BMI      
     Per quartile  Q4: range not provided OR=0.48(0.16-
1.39) 
Wald p=0.46. BMI      
Saǧlam et al 
2003(14) 
Turke
y 
Case-
control 
Comparison 
of C-C mean 
levels 
RIA Controls: Mean 
17.55(SE±7.20). Cases: 
Mean 27.33 (SE±12.50). 
p<0.001 
Not provided 
 
None Yes 21 50 
Siemińska et 
al 2018 (15) 
Poland Case-
control 
Comparison 
of C-C mean 
levels 
ELISA BPH controls: Mean 9.03 
(SE± 7.26). Cases: Mean 
9.79 (SE± 8.27), p>0.05. 
Not provided  BMI Yes 74 66 
Singh et al 
2010(16) 
India 
 
Case-
control 
Comparison 
of C-C mean 
levels 
ELISA 
 
Controls: Mean 5.15ng/ml 
(SD±10.11). Cases: Mean 
Not provided  Age Not 
stated 
30 30 
19.51ng/ml (SD±20.2). 
p=0.001 
Stattin et al 
2000(17) 
Swede
n 
Nested 
case-
control 
Per quartile RIA Q2: range not provided  OR=1.0(0.6–1.6)    Age Yes 200 397 
     Per quartile  Q3: range not provided  OR=0.7(0.4–1.1)   Age      
     Per quartile  Q4: range not provided  OR=0.9(0.6–1.6)  Not provided Age      
     Per quartile  Q2: range not provided OR=1.0(0.6–1.7)   Age, Testosterone, 
Estradiol, SHBG 
     
     Per quartile  Q3: range not provided OR=0.7(0.4–1.1)   Age, Testosterone, 
Estradiol, SHBG 
     
     Per quartile  Q4: range not provided OR=0.9(0.6–1.6)  Not provided Age, Testosterone, 
Estradiol, SHBG 
     
Stattin et al 
2003(18) 
Norwa
y 
Nested 
case-
control 
Per quintile 
(grouped as 
tertiles) 
RIA Q1: ≤2.6 Reference     Not 
stated 
149 298 
     Per quintile 
(grouped as 
tertiles) 
 Q2:-3 2.6 RR=2.4(1.3-4.2)   Age      
     Per quintile 
(grouped as 
tertiles) 
 Q4-5: >5.5 RR=1.5(0.8-2.7)  Not provided Age      
     Per quintile 
(grouped as 
tertiles) 
 Q2-3: 2.6 RR=2.4(1.3-4.5)   Age, BMI, insulin      
     Per quintile 
(grouped as 
tertiles) 
 Q4-5: >5.5 RR=1.5(0.7-3.2)  Not provided Age, BMI, insulin      
Stocks et al 
2007(19) 
Swede
n 
Nested 
case-
control 
Incremental RIA Per one unit increase OR=0.93(0.89-
0.97) 
p=0.002 Age Yes 392 392 
     Per quartile  Q1: <3.0 Reference          
     Per quartile  Q2: 3.0-4.5 OR=0.81(0.5-1.21)   Age      
     Per quartile  Q3: 4.5-6.9 OR=0.73(0.49-
1.09) 
  Age      
     Per quartile  Q4: >6.9 OR=0.55(0.36-
0.84) 
p=0.006 Age      
Tewari et al 
2013(20) 
India Case-
control 
Comparison 
of C-C mean 
levels 
Not stated BPH controls' Mean 37.51 
(SD±25.60). Cases: Mean 
55.48 (SD±40.26). 
p<0.0001. Units not 
provided.   
Not provided 
 
None Not 
stated 
95 95 BPH 
Touvier et al 
2012(21) 
France Nested 
case-
control 
  ELISA Q1: range not provided Reference     Yes 156 312 
     Per quartile  Q2: 2.4 OR=0.54(0.30-
0.96) 
  Age      
     Per quartile  Q3: 4.1 OR=1.02(0.59-
1.76) 
  Age      
     Per quartile  Q4: 6.6 OR=1.19(0.64-
2.22) 
P trend 0.3 Age      
 
 
 
Per quartile  Q2: 2.4 OR=0.47(0.22-
0.97) 
  Age, BMI, height, 
SU.VI.MAX 
intervention group 
 
  
   Per quartile  Q3: 4.1 OR=0.89(0.44-
1.77)  
  Age, BMI, height, 
SU.VI.MAX 
intervention group 
   
   Per quartile  Q4: 6.6 OR=0.69(0.27-
1.75) 
P=0.9 Age, BMI, height, 
SU.VI.MAX 
intervention group 
   
            
 
Table 1. Extracted data from studies analysing serum leptin levels and the incidence of PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of the mean; OR: Odd’s ratio; 
RR: risk ratio; BMI: body mass index; T: tertile; Q: quartile or quintile; PSA: prostate specific antigen; BPH: Benign prostate hyperplasia; WHR: waist-to-hip ratio, IGF-1: insulin-like growth factor-1; 
SHGB: sex hormone-binding globulin; SU.VI.MAX: The Supplementation en Vitamines et Mineraux Antioxydants study.  
 
 
 
 
 
 
 
 
 
Study Co
unt
ry 
Study 
design 
 Exposure 
category 
Detection 
assay 
Exposure metric 
(ng/ml) 
Risk 
Estima
te 
PInteraction/ P Matched factors/ 
Covariates 
Fasted 
blood 
High-
stage 
cases N 
Low-
stage 
controls 
N 
Arisan et 
al 
2009(1) 
Tur
key 
Case-
control 
 Comparison of Mean 
C-C levels 
ELISA Low-stage: Mean 14.78 
[no SD provided], High-
stage: Mean 15.24, 
p=0.027   
Not 
provided 
Not provided Age, BMI Yes 18 32 
Burton et 
al 
2013(22) 
UK Nested 
case-
control 
 Risk of high-stage 
per quartile 
ELISA Q1: 0.3–2.8 Referenc
e 
  
No 
  
 
   Risk of high-stage 
per quartile 
 Q2: 2.8–4.5 OR=0.50(0.32–0.78) Age  311 413 
 
   Risk of high-stage 
per quartile 
 Q3: 4.5–7.3 OR=0.83(0.54–1.28) Age    
 
   Risk of high-stage 
per quartile 
 Q4: 7.3–54.4 OR=0.9
6(0.62–
1.49)  
Differences across 
groups p=0.009 
Age    
Chang et 
al 
2001(23) 
US
A 
Case-
control 
 Risk of high-volume 
localised tumour 
RIA With high leptin (>7.12) OR=2.41(1.16-5.01) Age Not 
stated 
151 48 
 
   Risk of high-volume 
localised tumour 
 With high leptin (>7.12) OR=2.06(0.93-4.58) Age, BMI    
 
   Risk of high-volume 
localised tumour 
 With high leptin (>7.12) OR=2.35(1.01-5.44). Age, BMI, testosterone    
 
   Risk of high-volume 
localised tumour 
 With high leptin (>7.12) 
and high testosterone 
>1.32 ng/ml 
OR=9.73(2.05-46.24) Age, BMI     
Freedlan
d et al 
2005(24) 
US
A 
Case-
control 
 Risk of stage pT3 at 
RP, BMI ≤25 
ELISA Logistic regression OR=1.14(0.76–1.71) Age Not 
stated 
1 224 
    Risk of stage pT3 at 
RP, BMI 25-30 
 Logistic regression OR=1.21 (0.63–2.34) Age, BMI    
    Risk of stage pT3 at 
RP, BMI ≥30 
 Logistic regression OR=0.73 (0.28–1.87) Age, BMI    
Kang et 
al 2018 
(25) 
Sou
th 
Kor
ea 
Case-
control 
 Risk of stage ≤pT3  RIA Multivariate logistic 
regression analysis used to 
identify independent 
predictors for advanced 
tumour stage (≥pT3) 
OR=1.13(0.92-1.39), p=0.249 BMI Not 
stated 
1 24 
Lai et al 
2014(11) 
US
A 
Nested 
case-
control 
 Risk of Localised. 
Highest vs lowest 
quartile 
ELISA Q1: cutoff not provided, 
Q4 cutoffs of 4 batches: 
24.05, 25.24, 21.82, 11.41  
OR=0.8
5(0.67–
1.06) 
P=0.09 Age, PSA test before 
blood draw, Year, Time 
of day, season of blood 
draw 
Not 
presented
* 
156 1064 
 
   Risk of Localised. 
Highest vs lowest 
quartile 
 Q1: cutoff not provided, 
Q4 cutoffs of 4 batches: 
24.05, 25.24, 21.82, 11.41  
OR=0.8
8(0.66–
1.17) 
P=0.24 Age, PSA test before 
blood draw, Year, Time 
of day, season of blood 
draw, BMI, diabetes 
   
 
   Risk of Advanced. 
Highest vs lowest 
quartile 
 Q1: cutoff not provided, 
Q4 cutoffs of 4 batches: 
24.05, 25.24, 21.82, 11.41  
OR=0.9
4(0.58–
1.50) 
P=0.78 Age, PSA test before 
blood draw, Year, Time 
of day, season of blood 
draw 
 156 1064 
 
   Risk of Advanced. 
Highest vs lowest 
quartile 
 Q1: cutoff not provided, 
Q4 cutoffs of 4 batches: 
24.05, 25.24, 21.82, 11.41  
OR=0.7
7(0.43–
1.38) 
P=0.37 Age, PSA test before 
blood draw, Year, Time 
of day, season of blood 
draw, BMI, diabetes 
   
Li et al 
2010(12) 
US
A 
Nested 
case-
control 
 Risk of high-stage 
per quintile 
RIA Q1: 2.3(0.8–3.2) Referenc
e 
  
Not 
stated 
121 121 
 
   Risk of high-stage 
per quintile 
 Q2: 3.9(3.3–4.6) RR=0.96(0.43–2.14)  Age    
 
   Risk of high-stage 
per quintile 
 Q3: 5.5(4.7–6.5) RR=1.22
(0.54–
2.77) 
 
Age    
 
   Risk of high-stage 
per quintile 
 Q4: 8.0(6.6–10.0) RR=0.99
(0.44–
2.26) 
 
Age    
 
   Risk of high-stage 
per quintile 
 Q5: 14.1(10.1–50.6) RR=1.69
(0.67–
4.23)  
P=0.24 Age    
 
   Risk of high-stage 
per quintile 
 Q2: 3.9(3.3–4.6) RR=0.66(0.25–1.74)  Age, BMI, c-peptide    
 
   Risk of high-stage 
per quintile 
 Q3: 5.5(4.7–6.5) RR=0.58(0.19–1.79)  Age, BMI, c-peptide    
 
   Risk of high-stage 
per quintile 
 Q4: 8.0(6.6–10.0) RR=0.41(0.12–1.45)  Age, BMI, c-peptide    
 
 
 
 Risk of high-stage 
per quintile 
 Q5: 14.1(10.1–50.6) RR=0.94
(0.25–
3.51)  
P=0.81 Age, BMI, c-peptide    
    
Risk of PCa-specific 
mortality 
 
Q2: 3.9(3.3–4.6) 
HR=1.08
(0.58–
2.03)  Age 
 
94 
deaths 461 
    
Risk of PCa-specific 
mortality 
 
Q3: 5.5(4.7–6.5) 
HR=1.06
(0.56–
2.02)  Age 
 
  
    
Risk of PCa-specific 
mortality 
 
Q4: 8.0(6.6–10.0) 
HR=0.73
(0.36–
1.47)  Age 
 
  
    
Risk of PCa-specific 
mortality 
 
Q5: 14.1(10.1–50.6) 
HR=1.21
(0.65–
2.24) P=0.68 Age 
 
  
    
Risk of PCa-specific 
mortality 
 
Q2: 3.9(3.3–4.6) 
HR=1.03
(0.55–
1.94)  Age, BMI 
 
  
    
Risk of PCa-specific 
mortality 
 
Q3: 5.5(4.7–6.5) 
HR=0.94
(0.49–
1.80)  Age, BMI 
 
  
    
Risk of PCa-specific 
mortality 
 
Q4: 8.0(6.6–10.0) 
HR=0.59
(0.28–
1.22)  Age, BMI 
 
  
    
Risk of PCa-specific 
mortality 
 
Q5: 14.1(10.1–50.6) 
HR=0.82
(0.40–
1.68) P=0.47 Age, BMI 
 
  
    
Risk of PCa-specific 
mortality 
 
Q2: 3.9(3.3–4.6) 
HR=0.97
(0.49–
1.93)  Age, BMI, c-peptide 
 
  
    
Risk of PCa-specific 
mortality 
 
Q3: 5.5(4.7–6.5) 
HR=0.91
(0.46–
1.82)  Age, BMI, c-peptide 
 
  
    
Risk of PCa-specific 
mortality 
 
Q4: 8.0(6.6–10.0) 
HR=0.57
(0.26–
1.24)  Age, BMI, c-peptide 
 
  
    
Risk of PCa-specific 
mortality 
 
Q5: 14.1(10.1–50.6) 
HR=0.71
(0.32–
1.58) P=0.32 Age, BMI, c-peptide,  
 
  
    
Risk of PCa-specific 
mortality 
 
Q2: 3.9(3.3–4.6) 
HR=1.10
(0.54–
2.22)  
Age, BMI, c-peptide, 
stage, grade 
 
  
    
Risk of PCa-specific 
mortality 
 
Q3: 5.5(4.7–6.5) 
HR=0.90
(0.43–
1.87)  
Age, BMI, c-peptide, 
stage, grade 
 
  
    
Risk of PCa-specific 
mortality 
 
Q4: 8.0(6.6–10.0) 
HR=0.46
(0.20–
1.09)  
Age, BMI, c-peptide, 
stage, grade 
 
  
    
Risk of PCa-specific 
mortality 
 
Q5: 14.1(10.1–50.6) 
HR=0.66
(0.28–
1.53) P=0.24 
Age, BMI, c-peptide, 
stage, grade 
 
  
             
Saǧlam 
et al 
2003(14) 
Tur
key 
Case-
control 
 Comparison of Mean 
C-C levels 
RIA Low-stage: Mean 19.01 
(SE±2.72), High-stage: 
Mean 36.47 (SE±12.73), 
p<0.001 
Not 
provided 
 None Yes 10 11 
Tewari 
et al 
2013(20) 
Indi
a 
Case-
control 
 Risk of high-stage Not stated Low-stage: Mean 49.50 
(SD±39.70), High-stage: 
Mean 67.83 (SD39.19) 
[unit not provided] 
OR=1.01(1.00-1.02) None Not 
stated 
31 64 
 
Table 2. Extracted data from studies analysing serum leptin levels and the incidence of high-stage PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of the mean; OR: 
Odd’s ratio; RR: risk ratio; BMI: body mass index; T: tertile; Q: quartile or quintile; PSA: prostate specific antigen. *In the methods section it states that fasting was stratified and adjusted for although 
the stratified table is not provided in the results. 
 
Study Countr
y 
Study 
design 
Exposure 
category 
Detectio
n assay 
Exposure 
metric 
(ng/ml) 
Risk 
estimate 
PInteraction/P Covariates Fasted 
blood 
High-
grade 
cases 
Low 
grade 
contro
ls 
Classificati
on of 
Gleason 
Score 7 
Arisan et 
al 
2009(1) 
Turkey Case-
control 
Comparison 
of Mean C-C 
levels 
ELISA Low-grade: 
13.90, High-
grade: Mean 
15.98 [no SDs 
provided], 
p=0.038 
Not provided 
 
Age, BMI Yes 10 or 
11* 
8 or 24* Intermediate-
grade 
Baillarge
on et al 
2006(2) 
USA Nested 
case-
control 
Risk of high-
grade per 
tertile 
LabMAP T1: range not 
provided 
Reference 
  
Not 
stated 
40 85 Intermediate-
grade 
 
  Risk of high-
grade per 
tertile 
 T2: range not 
provided 
OR=1.26(0.4
8-3.31) 
 
Age, 
Race/ethnicity 
   
 
 
  Risk of high-
grade per 
tertile 
 T3: range not 
provided 
OR=1.20(0.4
8-3.01) 
P=0.85 Age, 
Race/ethnicity 
   
 
 
  Risk of high-
grade per 
tertile 
 T2: range not 
provided 
OR=1.24(0.4
4-3.50) 
 
Age, 
Race/ethnicity, 
BMI 
   
 
 
  Risk of high-
grade per 
tertile 
 T3: range not 
provided 
OR=1.12(0.4
3-2.97) 
P=0.83 Age, 
Race/ethnicity, 
BMI 
   
 
   Comparison 
of Mean C-C 
levels 
 Low-grade 
controls: Mean 
8.2pg/ml 
(SD±6.2pg/ml)
. High-grade 
cases: Mean 
9.6pg/ml (SD± 
9.4pg/ml) 
(p=0.032 
(Chi2/ t test, 
α=0.05)  
       
Burton et 
al 
2013(22) 
UK Nested 
case-
control 
Risk of high-
grade per 
quintile 
ELISA Q4: 8.0(6.6–
10.0) 
RR=0.99(0.4
4–2.26) 
 
Age No 307 416 Intermediate-
grade 
 
  Risk of high-
grade per 
quintile 
 Q5: 14.1(10.1–
50.6) 
RR=1.69(0.6
7–4.23) 
P=0.24 Age    
 
 
  Risk of high-
grade per 
quintile 
 Q2: 3.9(3.3–
4.6) 
RR=0.76(0.3
0–1.89 
 
Age, BMI, c-
peptide 
   
 
 
  Risk of high-
grade per 
quintile 
 Q3: 5.5(4.7–
6.5) 
RR=0.52(0.1
9–1.46 
 
Age, BMI, c-
peptide 
   
 
 
  Risk of high-
grade per 
quintile 
 Q4: 8.0(6.6–
10.0) 
RR=1.04(0.3
6–3.02) 
 
Age, BMI, c-
peptide 
   
 
 
  Risk of high-
grade per 
quintile 
 Q5: 14.1(10.1–
50.6) 
RR=1.29(0.4
4–3.80) 
P=0.34 Age, BMI, c-
peptide 
   
 
Duarte et 
al 2018 
(4) 
Portugal Case-
control 
Chi-square 
(χ2) of 
Gleason 
score 
(tumour 
aggressivene
ss) in relation 
ECLIA Not stated χ2 of Gleason 
score = 8.39 
P=0.136 None Not 
stated 
Not 
stated 
Not 
stated 
Not stated 
to clinical 
and 
biochemical 
profiles. 
Fontana 
et al 
2011(5) 
Argentin
a 
Case-
control 
Comparison 
of Mean C-C 
levels 
ELISA Low-grade: 
Mean 2.6 
(SEM±0.41), 
High-grade 
Mean 
12.1(SEM±3.0
1), p<0.0001 
.Not 
provided 
 
Age, BMI Not 
stated 
9 12 Intermediate-
grade 
Fowke et 
al 
2013(26) 
USA Nested 
case-
control 
Risk of Low-
grade 
RIA Dichotomised 
at Median, 
High >8.49 vs. 
Low ≤8.49 
OR=1.88(1.0
5-3.37) 
p=0.03 Age Not 
stated 
100 100 Intermediate-
grade 
 
  Risk of High-
grade  
 Dichotomised 
at Median, 
High >8.49 vs. 
Low ≤8.49 
OR=1.11(0.6
3-1.96) 
p=0.71 Age    
 
Lai et al 
2014(11) 
USA Nested 
case-
control 
Risk of low-
grade. 
Highest vs 
lowest 
quartile 
ELISA Q1: cutoff not 
provided, Q4 
cutoffs of 4 
batches: 24.05, 
25.24, 21.82, 
11.41  
OR=0.85(0.6
6–1.10) 
P=0.13 Age, PSA, Year, 
Time of day, 
season of blood 
draw 
Not 
presente
d* 
477 736 Intermediate-
grade 
 
  Risk of low-
grade. 
Highest vs 
lowest 
quartile 
 Q1: cutoff not 
provided, Q4 
cutoffs of 4 
batches: 24.05, 
25.24, 21.82, 
11.41  
OR=0.92(0.6
7–1.26) 
P=0.41  Age, PSA, Year, 
Time of day, 
season of blood 
draw, BMI, 
diabetes 
   
 
 
  Risk of high-
grade. 
Highest vs 
lowest 
quartile 
 Q1: cutoff not 
provided, Q4 
cutoffs of 4 
batches: 24.05, 
25.24, 21.82, 
11.41  
OR=0.85(0.6
3–1.14) 
P=0.19 Age, PSA, Year, 
Time of day, 
season of blood 
draw 
   
 
 
  Risk of high-
grade. 
Highest vs 
lowest 
quartile 
 Q1: cutoff not 
provided, Q4 
cutoffs of 4 
batches: 24.05, 
25.24, 21.82, 
11.41  
OR=0.81(0.5
6–1.18) 
P=0.18 Age, PSA, Year, 
Time of day, 
season of blood 
draw, BMI, 
diabetes 
   
 
Li et al 
2010(12) 
USA Nested 
case-
control 
Risk of high-
grade per 
quintile 
RIA Q1: 2.3(0.8–
3.2) 
Reference 
  
Not 
stated 
124 124 High-grade 
 
  Risk of high-
grade per 
quintile 
 Q2: 3.9(3.3–
4.6) 
RR=1.02(0.4
6–2.22) 
 
Age    
 
 
  Risk of high-
grade per 
quintile 
 Q3: 5.5(4.7–
6.5) 
RR=0.83(0.3
7–1.85) 
 
Age    
 
 
  Risk of high-
grade per 
quintile 
 Q4: 8.0(6.6–
10.0) 
RR=1.58(0.6
8–3.68) 
 
Age    
 
 
  Risk of high-
grade per 
quintile 
 Q5: 14.1(10.1–
50.6) 
RR=1.74(0.7
6–4.00) 
P=0.12 Age    
 
 
  Risk of high-
grade per 
quintile 
 Q2: 3.9(3.3–
4.6) 
RR=0.76(0.3
0–1.89) 
 
Age, BMI, c-
peptide 
   
 
 
  Risk of high-
grade per 
quintile 
 Q3: 5.5(4.7–
6.5) 
RR=0.52(0.1
9–1.46) 
 
Age, BMI, c-
peptide 
   
 
 
  Risk of high-
grade per 
quintile 
 Q4: 8.0(6.6–
10.0) 
RR=1.04(0.3
6–3.02) 
 
Age, BMI, c-
peptide 
   
 
 
  Risk of high-
grade per 
quintile 
 Q5: 14.1(10.1–
50.6) 
RR=1.29(0.4
4–3.80) 
P=0.34 Age, BMI, c-
peptide 
   
 
Saǧlam et 
al 
2003(14) 
Turkey Case-
control 
Comparison 
of Mean C-C 
levels 
RIA Low-grade: 
Mean 
19.52(SE±2.02
), High-grade: 
Mean 
33.15ng/ml 
(SE±6.36), 
p=0.003 
Not provided 
 
None Yes 10 11 Intermediate-
grade 
Serretta et 
al 2018 
(27) 
Case-
control 
Not 
stated  
Risk of 
Gleason 
score 4 and 5 
ELISA Median (25th-
75th 
percentile): 
Low-grade 
1.15(0.24-
2.64), high-
grade 
0.88(0.11-3.9), 
p=0.18.  
Not provided  BMI Not 
stated 
68 81 Not stated 
Siemińsk
a et al 
2018 (15) 
Poland Case-
control 
Comparison 
of C-C mean 
levels 
ELISA Low-grade: 
Mean 7.73 
(SD± 7.01), 
high-grade: 
13.34 (SD± 
11.20) 
Not provided  Age, BMI Yes 22 24 Intermediate-
grade 
Singh et 
al 
2010(16) 
India Case-
control 
Comparison 
of Mean C-C 
levels 
ELISA Data not 
provided 
Not provided 
 
Age Not 
stated 
12 4 High-grade 
Tewari et 
al 
2013(20) 
India Case-
control 
Risk of high-
grade 
Not 
stated 
Low-grade: 
Mean 9.84 
(SD±5.68), 
High-grade: 
Mean 79.77 
(SD±24.47) 
[unit not 
provided] 
OR=1.31(1.1
0-1.56)  
 
 
None Not 
stated 
62 33 not stated 
 
Table 3. Extracted data from studies analysing serum leptin levels and the incidence of high-grade PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of the mean; OR: 
Odd’s ratio; RR: risk ratio; BMI: body mass index; T: tertile; Q: quartile or quintile; PSA: prostate specific antigen, ECLIA: electrochemiluminescent assay. *As presented in tables 1 and 2, 
respectively. *In the methods section it states that fasting was stratified and adjusted for although the stratified table is not provided in the results. 
 
 
Study Country Study 
design 
Exposure 
category  
Detection 
assay 
Exposure metric 
(μg/mL) 
Risk estimate PInteraction/ P Covariates Fasted 
blood 
Cases Cancer-
free 
controls 
Arisan et al 
2009(1) 
Turkey Case-
control 
Compared Mean C-
C levels 
ELISA Controls: Mean 18.4 
(SEM not 
provided). Cases 
Mean not provided. 
Not provided  Age, BMI Yes 50 50 
Baillargeon 
et al 2006(2) 
USA Nested 
case-
control 
Per tertile LabMAP T1: range not 
provided 
Reference 
  
Not 
stated 
228 239 
 
 
 
Per tertile  T2: range not 
provided 
OR=0.83(0.43-1.58) Age, Race/ethnicity    
 
 
 
Per tertile  T3: range not 
provided 
OR=0.87(0.46-
1.65),  
P=0.24.  Age, Race/ethnicity    
 
 
 
Per tertile  T2: range not 
provided 
OR=0.80(0.33-1.97) Age, Race/ethnicity, BMI    
 
 
 
Per tertile  T3: range not 
provided 
OR=0.81(0.34-
1.91) 
P=0.44. Age, Race/ethnicity, BMI    
 
 
 
Highest vs lowest 
tertile 
 Tertiles not 
provided 
OR=0.87(0.46-
1.65)  
P=0.24.  Age, Race/ethnicity    
 
 
 
Highest vs lowest 
tertile 
 Tertiles not 
provided 
OR=0.81(0.34-
1.91) 
P=0.44. Age, Race/ethnicity, BMI    
Goktas et al 
2005(28) 
Turkey Case-
control 
Compared Mean C-
C levels 
RIA Controls: Mean 
16.2(SD±4.1). 
Cases: Mean 
5.3(SD±1.6). 
P<0.001 
Not provided  None Yes 30 36 
Grosman et 
al 2010(29) 
Argentina Case-
control 
Compared Median 
C-C levels 
RIA Controls: Median 
20.5(Range 4.6–
48.5) Cases: Median 
Not provided  Age, BMI Yes 25 25 
10.3(Range 3.7–
28.5), p=0.049 
Housa et al 
2007(30) 
Czech 
Republic 
Case-
control 
Compared Mean C-
C levels 
ELISA BPH controls: Mean 
0.02047 
(SD±0.01013), 
Cases: Mean 
0.01868(SD± 
0.00775) [converted 
from ng/ml], p=0.64 
Not provided  None Yes 
 
43 25 BPH 
Ikeda et al 
2015(31) 
Japan Case-
control 
Compared Mean C-
C levels 
Latex particle-
enhanced 
turbidimetric 
immunoassay*  
Controls: Mean 
7.63(No SD 
provided), Cases: 
Mean 9.86, 
p=0.0049 
Not provided  None Not 
stated 
24 2816 
Li et al 
2010(12) 
USA Nested 
case-
control 
Per quintile RIA Q1: 2.8(0.3–3.8) Reference 
  
Not 
stated 
654 644 
 
 
 
Per quintile  Q2: 4.7(3.9–5.5) RR=0.86(0.59–1.26) Age[matched]    
 
 
 
Per quintile  Q3: 6.4(5.6–7.2) RR=0.85(0.58–1.25) Age[matched]    
 
 
 
Per quintile  Q4: 8.6(7.3–10.4) RR=1.04(0.73–1.49) Age[matched]    
 
 
 
Per quintile  Q5: 13.1(10.5–31.9) RR=0.69(0.47–
1.03) 
P=0.18  Age[matched]    
 
 
 
Per quintile  Q2: 4.7(3.9–5.5) RR=0.82(0.53–1.27) Age, BMI, c-peptide    
 
 
 
Per quintile  Q3: 6.4(5.6–7.2) RR=1.00(0.66–1.53) Age, BMI, c-peptide    
 
 
 
Per quintile  Q4: 8.6(7.3–10.4) RR=1.13(0.75–1.69) Age, BMI, c-peptide    
 
 
 
Per quintile  Q5: 13.1(10.5–31.9) RR=0.73(0.46–
1.14) 
P=0.39 Age, BMI, c-peptide    
Medina et al 
2013(32) 
USA Nested 
case-
control 
Compared Median 
C-C levels 
ELISA Controls: Median 
4.52(SD±3.25–
6.15). Cases: 
Median 
4.52(SD±3.03–
6.59). No p-value 
provided (only 
shown when <0.05) 
Not provided  None Not 
stated 
228 239 
Michalakis et 
al 2007(33) 
Greece Case-
control 
Per quartile RIA Q1: (0.0009-0.0053) 
[converted from 
ng/ml] 
Reference 
  
Yes 75 150 
 
 
 
Per quartile  Q2: (0.0053-0.0087) OR=0.74(0.28– 1.94) Age    
 
 
 
Per quartile  Q3: (0.0087– 
0.0137) 
OR=0.27(0.11– 0.67) Age    
 
 
 
Per quartile  Q4: (0.0137–
0.0432)  
OR=0.31(0.13–
0.77) 
p<0.01 Age    
 
 
 
Per quartile  Q2: (0.0053-0.0087) OR=0.70(0.27– 1.86) Age, BMI    
 
 
 
Per quartile  Q3: (0.0087– 
0.0137) 
OR=0.27(0.11– 0.67) Age, BMI    
 
 
 
Per quartile  Q4: (0.0137–
0.0432)  
OR=0.29(0.12–
0.73) 
p=<0.01 Age, BMI    
Michalakis et 
al 2015(34) 
Greece Case-
control 
Incrememental RIA Effect of 
adiponectin on 
identifying PCa  
OR=0.931(0.888-0.977) None Yes 75 150 
 
 
 
Incrememental  Effect of 
adiponectin on 
identifying PCa  
OR=0.912(0.85-
0.98) 
p=0.016 (of 
multivariate OR) 
Age, BMI, Smoking, Cholesterol   
Nishimura et 
al 2012(13) 
Japan Case-
control 
Per quartile ELISA Q1: range not 
provided 
Reference 
  
Not 
stated 
54 70 BPH 
 
 
 
Per quartile  Q2: range not 
provided 
OR=1.18(0.42-3.4) Age    
 
 
 
Per quartile  Q3: range not 
provided 
OR=1.06(0.33-3.39) Age    
 
 
 
Per quartile  Q4: range not 
provided 
OR=3.05(1.08-
9.15) 
Wald p=0.1 Age    
 
 
 
Highest vs lowest  Q1-3 vs 4 OR=2.79(1.25-
6.43) 
Wald p=0.014 Age    
 
 
 
Per quartile  Q2: range not 
provided 
OR=2.44(0.86-7.24) BMI    
 
 
 
Per quartile  Q3: range not 
provided 
OR=2.61(0.93-7.67) BMI    
 
 
 
Per quartile  Q4: range not 
provided 
OR=1.77(0.62-
5.19) 
Wald p=0.27 BMI    
Tewari et al 
2013(20) 
India Case-
control 
Compared Mean C-
C levels 
Not stated BPH controls: Mean 
114.87 (SD±13.22. 
Cases Mean 18.64 
(SD±20.23), 
p<0.0001. Units not 
provided 
Not provided  None Not 
stated 
95 95 BPH 
Touvier et al 
2012(21) 
France Nested 
case-
control 
Per quartile ELISA Q1: cutoff not 
provided 
Reference 
  
Yes 156 312 
 
 
 
Per quartile  Q2: 4.3 OR=0.92(0.54-1.58) Age    
 
 
 
Per quartile  Q3: 6.4 OR=0.99(0.57-1.71) Age    
 
 
 
Per quartile  Q4: 9.2 OR=1.10(0.64-
1.90) 
P=0.7  Age    
 
 
 
Per quartile  Q2: 4.3 OR=0.90(0.45-1.80) Age, BMI, Height, 
SU.VI.MAX intervention 
group 
   
 
 
 
Per quartile  Q3: 6.4 OR=1.38(0.69-2.76) Age, BMI, Height, 
SU.VI.MAX intervention 
group 
   
 
 
 
Per quartile  Q4: 9.2 OR=1.34(0.68-
2.61) 
P=0.3 Age, BMI, Height, 
SU.VI.MAX intervention 
group 
   
 
Table 4. Extracted data from studies analysing serum adiponectin levels and the incidence of PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of the mean; OR: Odd’s 
ratio; RR: risk ratio; BMI: body mass index; T: tertile; Q: quartile or quintile; PSA: prostate specific antigen; BPH: Benign prostate hyperplasia; WHR: waist-to-hip ratio, IGF-1: insulin-like growth 
factor-1; SHGB: sex hormone-binding globulin; SU.VI.MAX: The Supplementation en Vitamines et Mineraux Antioxydants study. *Human adiponectin latex kit; Otsuka Pharmaceutical Co., Tokyo, 
Japan. 
 
 
Study Population Stu
dy 
desi
gn 
Exposure 
category 
Detection 
assay 
Exposure 
metric 
(μg/mL) 
Risk 
Estimate 
PInteractio
n/ P 
Covariates Faste
d 
blood 
High
-
stage 
cases 
Low-
stage 
control
s 
Arisan et 
al 
2009(1) 
Turkey Case
-
contr
ol 
Compared Mean C-
C levels 
ELISA Low-stage: 
Mean 8.9, High-
stage: Mean 5.5 
[no SD 
provided], 
p=0.044 
Not provided 
 
Age, BMI Yes 18 32 
Burton 
et al 
2013(22) 
UK Nest
ed 
case-
contr
ol 
Risk of high-stage 
per quartile 
ELISA Q1: 0.9-4.5 Reference 
 
Age No 311 413 
 
  
Risk of high-stage 
per quartile 
 Q2: 4.5-6.5 OR=0.81(0.53
–1.25) 
 
Age    
 
  
Risk of high-stage 
per quartile 
 Q3: 6.5-9.7 OR=0.67(0.43
–1.03) 
 
Age    
 
  
Risk of high-stage 
per quartile 
 Q4: 9.7-37.2 OR=0.81(0.52
–1.25) 
p=0.35 Age    
 
  
Risk of high-stage 
per log (unit) 
 
 
OR=0.86(0.66
-1.11) 
 
Age    
 
  
Risk of high-stage 
per quartile, BMI < 
25  
 Q1: 0.9-4.5 Reference 
 
Age    
 
  
Risk of high-stage 
per quartile, BMI < 
25  
 Q2: 4.5-6.5 OR=2.10(0.55
-8.06) 
 
Age    
 
  
Risk of high-stage 
per quartile, BMI < 
25  
 Q3: 6.5-9.7 OR=1.03(0.32
-3.38) 
 
Age    
 
  
Risk of high-stage 
per quartile, BMI < 
25  
 Q4: 9.7-37.2 OR=1.77(0.58
-5.45) 
p=0.46 Age    
 
  
Risk of high-stage 
per log (unit), BMI < 
25  
 
 
OR=1.48(0.77
-2.82) 
 
Age    
 
  
Risk of high-stage 
per quartile, BMI ≥ 
25  
 Q1: 0.9-4.5 Reference 
 
Age    
 
  
Risk of high-stage 
per quartile, BMI ≥ 
25  
 Q2: 4.5-6.5 OR=0.61(0.34
-1.08) 
 
Age    
 
  
Risk of high-stage 
per quartile, BMI ≥ 
25  
 Q3: 6.5-9.7 OR=0.52(0.28
-0.93) 
 
Age    
 
  
Risk of high-stage 
per quartile, BMI ≥ 
25  
 Q4: 9.7-37.2 OR=0.55(0.30
-1.02) 
p=0.1 Age    
 
  
Risk of high-stage 
per log (unit), BMI ≥ 
25  
 
 
OR=0.62(0.42
-0.90) 
p=0.006 Age    
Freedlan
d et al 
2005 
(35) 
USA Case
-
contr
ol 
Risk of ≥pT3 at RP 
per quartile   
ELISA Q1: range not 
provided 
Reference  Age Not 
stated 
78 158 
     Q2: range not 
provided 
OR=0.59 
(0.27–1.30)  
 Age    
     Q3: range not 
provided 
OR=0.69 
(0.32–1.51)  
 Age    
     Q4: range not 
provided 
OR=1.03 
(0.49–2.18) 
p=0.75 Age    
     Q2-4: range not 
provided 
OR=0.74 
(0.39–1.39)  
p=0.35 Age    
     Q2: range not 
provided 
OR=0.58 
(0.26–1.29)  
 Age, BMI    
     Q3: range not 
provided 
OR=0.68 
(0.31–1.49)  
 Age, BMI    
     Q4: range not 
provided 
OR=1.01 
(0.47–2.16)  
p=0.77 Age, BMI    
     Q2-4: range not 
provided 
OR=0.76 
(0.41–1.40)  
p=0.38 Age, BMI    
Goktas 
et al 
2005(28) 
Turkey Case
-
contr
ol 
Compared Mean C-
C levels 
RIA Low-stage: 
Mean 
6.0(SD±1.7), 
High-stage: 
Mean 
4.7(SD±1.2), 
p=0.012 
Not provided 
 
None Yes 16 14 
Housa et 
al 
2007(30) 
Czech 
Republic 
Case
-
contr
ol 
Compared Mean C-
C levels 
ELISA Low-stage: 
Mean 0.01451 
(SD± 0.00492), 
High-stage: 
Mean 0.02141 
Not provided 
 
None Yes 26 17 
(SD±0.00812), 
p=0.003 
Ikeda et 
al 
2015(31) 
Japan Case
-
contr
ol 
Risk of high-risk by 
adiponectin and BMI 
Latex 
particle-
enhanced 
turbidimetric 
immunoassa
y* 
High 
adiponectin 
(≥6.7 median), 
High BMI (≥25) 
CDR=1.670 
 
Age, BMI Not 
stated 
4 20 
 
  
Risk of high-risk by 
adiponectin and BMI 
 High 
adiponectin 
(≥6.7 median), 
Low BMI (<25) 
CDR=0.725 
 
Age, BMI    
 
  
Risk of high-risk by 
adiponectin and BMI 
 Low adiponectin 
(<6.7 median), 
High BMI (≥25) 
CDR=0.577 
 
Age, BMI    
 
  
Risk of high-risk by 
adiponectin and BMI 
 Low adiponectin 
(<6.7 median), 
Low BMI (<25) 
CDR=0.633 
 
Age, BMI    
 
  
CDR of risk by 
adiponectin 
 High 
adiponectin 
(≥6.7 median), 
Low/intermediat
e risk PCa  
CDR=0.717. 
 
Age    
 
  
CDR of risk by 
adiponectin 
 High 
adipoenctin 
(≥6.7 median), 
High risk PCa  
CDR0.254 
 
Age    
 
  
CDR of risk by 
adiponectin 
 Low adiponectin 
(<6.7 median). 
Low/intermediat
e-risk PCa 
CDR=0.294 
 
Age    
 
  
CDR of risk by 
adiponectin 
 Low adiponectin 
(<6.7 median), 
High-risk PCa 
CDR=0.323 
 
Age    
Kang et 
al 2018 
(25) 
South Korea Case
-
contr
ol 
 Risk of stage 
≤pT3  
ELISA  Multivariate 
logistic 
regression 
analysis used 
to identify 
independent 
predictors for 
advanced 
tumour stage 
(≥pT3) 
OR=0.97(0.88-
1.06), p=0.534 
BMI Not 
stated 
1 24 
Li et al 
2010(12) 
USA Nest
ed 
case-
Risk of lethal-stage 
per quintile 
RIA Q1: 2.8(0.3–3.8) Reference 
  
Not 
stated 
121 121 
contr
ol 
 
  
Risk of lethal-stage 
per quintile 
 Q2: 4.7(3.9–5.5) RR=0.69(0.27
–1.76) 
 
Age    
 
  
Risk of lethal-stage 
per quintile 
 Q3: 6.4(5.6–7.2) RR=0.70(0.24
–2.03) 
 
Age    
 
  
Risk of lethal-stage 
per quintile 
 Q4: 8.6(7.3–
10.4) 
RR=0.53(0.21
–1.32) 
 
Age    
 
  
Risk of lethal-stage 
per quintile 
 Q5: 13.1(10.5–
31.9) 
RR=0.25(0.07
–0.87) 
P=0.02 Age    
 
  
Risk of lethal-stage 
per quintile 
 Q2: 4.7(3.9–5.5) RR=0.77(0.26
–2.26) 
 
Age, BMI, c-peptide    
 
  
Risk of lethal-stage 
per quintile 
 Q3: 6.4(5.6–7.2) RR=0.97(0.26
–3.53) 
 
Age, BMI, c-peptide    
 
  
Risk of lethal-stage 
per quintile 
 Q4: 8.6(7.3–
10.4) 
RR=0.69(0.24
–1.98) 
 
Age, BMI, c-peptide    
 
  
Risk of lethal-stage 
per quintile 
 Q5: 13.1(10.5–
31.9) 
RR=0.61(0.12
–2.99) 
P=0.44 Age, BMI, c-peptide    
 
  
Risk of PCa-specific 
mortality 
 Q2: 4.7(3.9–5.5) HR=0.81(0.45
–1.47) 
 
Age  90 
deaths 
440 
 
  
Risk of PCa-specific 
mortality 
 Q3: 6.4(5.6–7.2) HR=0.69(0.37
–1.30) 
 
Age    
 
  
Risk of PCa-specific 
mortality 
 Q4: 8.6(7.3–
10.4) 
HR=0.69(0.39
–1.23) 
 
Age    
 
  
Risk of PCa-specific 
mortality 
 Q5: 13.1(10.5–
31.9) 
HR=0.39(0.17
–0.85) 
P=0.02 Age    
 
  
Risk of PCa-specific 
mortality 
 Q2: 4.7(3.9–5.5) HR=0.83(0.46
–1.49) 
 
Age, BMI    
 
  
Risk of PCa-specific 
mortality 
 Q3: 6.4(5.6–7.2) HR=0.73(0.39
–1.36) 
 
Age, BMI    
 
  
Risk of PCa-specific 
mortality 
 Q4: 8.6(7.3–
10.4) 
HR=0.76(0.42
–1.37) 
 
Age, BMI    
 
  
Risk of PCa-specific 
mortality 
 Q5: 13.1(10.5–
31.9) 
HR=0.42(0.19
–0.92) 
P=0.03 Age, BMI    
 
  
Risk of PCa-specific 
mortality 
 Q2: 4.7(3.9–5.5) HR=0.87(0.45
–1.65) 
 
Age, BMI, c-peptide    
 
  
Risk of PCa-specific 
mortality 
 Q3: 6.4(5.6–7.2) HR=0.69(0.35
–1.36) 
 
Age, BMI, c-peptide    
 
  
Risk of PCa-specific 
mortality 
 Q4: 8.6(7.3–
10.4) 
HR=0.87(0.46
–1.62) 
 
Age, BMI, c-peptide    
 
  
Risk of PCa-specific 
mortality 
 Q5: 13.1(10.5–
31.9) 
HR=0.36(0.14
–0.90) 
P=0.04 Age, BMI, c-peptide,     
 
  
Risk of PCa-specific 
mortality 
 Q2: 4.7(3.9–5.5) HR=0.97(0.50
–1.88) 
 
Age, BMI, c-peptide, 
stage, grade 
   
 
  
Risk of PCa-specific 
mortality 
 Q3: 6.4(5.6–7.2) HR=0.58(0.28
–1.17) 
 
Age, BMI, c-peptide, 
stage, grade 
   
 
  
Risk of PCa-specific 
mortality 
 Q4: 8.6(7.3–
10.4) 
HR=0.79(0.40
–1.53) 
 
Age, BMI, c-peptide, 
stage, grade 
   
 
  
Risk of PCa-specific 
mortality 
 Q5: 13.1(10.5–
31.9) 
HR=0.35(0.14
–0.89) 
P=0.03 Age, BMI, c-peptide, 
stage, grade 
   
Stevens 
et al 
2014(36) 
USA Nest
ed 
case-
contr
ol 
Risk of aggressive 
per quartile 
ELISA Q1: <6.178 Reference 
  
Not 
stated 
69 194 
 
  
Risk of aggressive 
per quartile 
 Q2: 6.178-7.878 OR=1.05(0.62
-1.78) 
 
Age, family history of 
PCa, BMI, physical 
activity in metabolic 
equivalents, total calcium 
intake, and energy intake 
   
 
  
Risk of aggressive 
per quartile 
 Q3: 7.879-
11.108 
OR=1.43(0.87
-2.36) 
 
Age, family history of 
PCa, BMI, physical 
activity in metabolic 
equivalents, total calcium 
intake, and energy intake 
   
 
  
Risk of aggressive 
per quartile 
 Q4: ≥11.109 OR=1.11(0.64
-1.93) 
P=0.59 Age, family history of 
PCa, BMI, physical 
activity in metabolic 
equivalents, total calcium 
intake, and energy intake 
   
 
  
Risk of aggressive 
per quartile 
 Q2: 6.178-7.878 OR=0.76(0.38
-1.52) 
 
Age, family history of 
PCa, BMI, physical 
activity in metabolic 
equivalents, total calcium 
intake, and energy intake 
   
 
  
Risk of aggressive 
per quartile 
 Q3: 7.879-
11.108 
OR=1.10(0.58
-2.11) 
 
Age, family history of 
PCa, BMI, physical 
activity in metabolic 
equivalents, total calcium 
intake, and energy intake 
   
 
  
Risk of aggressive 
per quartile 
 Q4: ≥11.109 OR=0.70(0.33
-1.49) 
P=0.56 Age, family history of 
PCa, BMI, physical 
activity in metabolic 
equivalents, total calcium 
intake, and energy intake 
   
Tewari 
et al 
2013(20) 
India Case-
control 
Risk of high-stage Not stated Increased 
adiponectin 
(increment not 
specified) 
OR 
=0.94(0.88-
0.99)  
 
None Not 
stated 
31 64 
 
Table 5. Extracted data from studies analysing serum adiponectin levels and the incidence of high-stage PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of the mean; 
OR: Odd’s ratio; BMI: body mass index; RR: risk ratio; HR: Hazard ratio; CDR: cancer detection rate; T: tertile; Q: quartile or quintile. 
 
 
Study Study 
desig
n 
Populatio
n 
Exposure 
category 
Detectio
n assay 
Exposure 
metric (μg 
/ml) 
Risk estimate PInteractio
n/ P 
Covariates Faste
d 
blood 
High-
grade 
cases 
Low 
grade 
control
s 
Classificatio
n of Gleason 
Score 7 
Arisan et 
al 2009(1) 
Case-
control 
Turkey Compared 
Mean C-C 
levels 
ELISA Low-grade: 
Mean 9.2, 
High-grade: 
Mean 4.1 [no 
SDs 
provided], 
p=0.0021 
Not provided  Age, BMI Yes 10 or 
11* 
8 or 24* Intermediate-
grade 
Baillargeo
n et al 
2006(2) 
Nested 
case-
control 
USA Risk of high-
grade per 
tertile 
LabMAP T1: range not 
provided 
Reference 
  
Not 
stated 
40 85 High-grade 
   
Risk of high-
grade per 
tertile 
 T2: range not 
provided 
OR=1.48(0.57-
3.82) 
 
Age, 
Race/ethnicity 
   
 
   
Risk of high-
grade per 
tertile 
 T3: range not 
provided 
OR=1.93(0.74-
5.10) 
p=0.3 Age, 
Race/ethnicity 
   
 
   
Risk of high-
grade per 
tertile 
 T2: range not 
provided 
OR=1.17(0.41-
3.33) 
 
Age, 
Race/ethnicity, 
BMI 
   
 
 
  
Risk of high-
grade per 
tertile 
 T3: range not 
provided 
OR=1.45(0.55-
3.32 
p=0.49 Age, 
Race/ethnicity, 
BMI 
   
 
Burton et 
al 
2013(22) 
Nested 
case-
control 
UK Risk of high-
grade per 
quartile 
ELISA Q1: 0.9-4.5 OR=1.00[Referen
ce] 
 
None No 307 416 High-grade 
   
Risk of high-
grade per 
quartile 
 Q2: 4.5-6.5 OR=0.84(0.55-
1.30) 
 
None    
 
   
Risk of high-
grade per 
quartile 
 Q3: 6.5-9.7 OR=0.81(0.53-
1.24) 
 
None    
 
   
Risk of high-
grade per 
quartile 
 Q4: 9.7-37.2 OR=0.89(0.58-
1.36) 
p=0.79 None    
 
   
Risk of high-
grade per log 
(unit) 
 
 
OR=0.91(0.70-
1.18) 
 
None    
 
   
Risk of high-
grade per 
quartile, BMI 
< 25  
 Q1: 0.9-4.5 OR=1.00[Referen
ce] 
 
None    
 
   
Risk of high-
grade per 
 Q2: 4.5-6.5 OR=0.84(0.27-
2.61) 
 
None    
 
quartile, BMI 
< 25     
Risk of high-
grade per 
quartile, BMI 
< 25  
 Q3: 6.5-9.7 OR=0.84(0.30-
2.35) 
 
None    
 
   
Risk of high-
grade per 
quartile, BMI 
< 25  
 Q4: 9.7-37.2 OR=0.93(0.35-
2.49) 
p=0.98 None    
 
   
Risk of high-
grade per log 
(unit), BMI < 
25  
 
 
0.88(0.49-1.57) 
 
None    
 
   
Risk of high-
grade per 
quartile, BMI 
≥ 25  
 Q1: 0.9-4.5 OR=1.00[Referen
ce] 
 
None    
 
   
Risk of high-
grade per 
quartile, BMI 
≥ 25  
 Q2: 4.5-6.5 OR=0.75(0.44-
1.30) 
 
None    
 
   
Risk of high-
grade per 
quartile, BMI 
≥ 25  
 Q3: 6.5-9.7 OR=0.89(0.51-
1.55) 
 
None    
 
   
Risk of high-
grade per 
quartile, BMI 
≥ 25  
 Q4: 9.7-37.2 OR=0.86(0.48-
1.55) 
p=0.79 None    
 
   
Risk of high-
grade per log 
(unit), BMI ≥ 
25  
 
 
OR=0.90(0.63-
1.28) 
 
None    
 
Fowke et 
al 
2013(26) 
Nested 
case-
control 
USA Risk of low 
grade 
RIA Dichotomised 
at Median, 
Low 
<0.02015 vs. 
High  
≥0.02015 
OR=1.46(0.80-
2.65) 
p=0.22 Age Not 
stated 
100 100 High-grade 
   
Risk of high-
grade 
 Dichotomised 
at Median, 
Low 
<0.02015 vs. 
High  
≥0.02015 
OR=0.96(0.53-
1.76) 
p=0.90 Age    
 
Freedland 
et al 2005 
(35) 
Case-
control 
 Risk of high-
grade 
ELISA Q1: range not 
provided 
Reference  Age Not 
stated 
65 171 High-grade 
     Q2: range not 
provided 
OR=0.77 (0.34–
1.75)  
 Age     
     Q3: range not 
provided 
OR=0.60 (0.27–
1.37)  
 Age     
     Q4: range not 
provided 
OR=0.68 (0.30–
1.55)  
p=0.33 Age     
     Q2-4: range 
not provided 
OR=0.68 (0.35–
1.32)  
p=0.26 Age     
     Q2: range not 
provided 
OR=0.77 (0.34–
1.77)  
 Age, BMI     
     Q3: range not 
provided 
OR=0.61 (0.26–
1.40)  
 Age, BMI     
     Q4: range not 
provided 
OR=0.67 (0.29–
1.53)  
p=0.35 Age, BMI     
     Q2-4: range 
not provided 
OR=0.69 (0.35–
1.34) 
p=0.27 Age, BMI     
Goktas et 
al 
2005(28) 
Case-
control 
Turkey Compared 
Mean C-C 
levels 
RIA Low-grade: 
Mean 6.7 (SD 
± 1.8), High-
grade: Mean 
3.8 (SD±0.7), 
p<0.001 
Not provided 
 
None Yes 9 8 Intermediate-
grade 
Housa et 
al 
2007(30) 
Case-
control 
Czech 
Republic 
Compared 
Mean C-C 
levels 
ELISA Low-grade: 
Mean 0.0196 
(SD±0.0883), 
High-grade: 
Mean 17.13 
(SD±0.0538), 
p=0.32 
Not provided  None Yes 7 19 High-grade 
Li et al 
2010(12) 
Nested 
case-
control 
USA Risk of high-
grade per 
quartile 
RIA Q1: 2.8(0.3–
3.8) 
   
Not 
stated 
124 124 Intermediate-
grade 
   
Risk of high-
grade per 
quartile 
 Q2: 4.7(3.9–
5.5) 
RR=0.83(0.32–
2.11) 
 
Age    
 
   
Risk of high-
grade per 
quartile 
 Q3: 6.4(5.6–
7.2) 
RR=0.47(0.20–
1.10) 
 
Age    
 
   
Risk of high-
grade per 
quartile 
 Q4: 8.6(7.3–
10.4) 
RR=0.95(0.42–
2.16) 
 
Age    
 
   
Risk of high-
grade per 
quartile 
 Q5: 
13.1(10.5–
31.9) 
RR=0.49(0.20–
1.22) 
p=0.25 Age    
 
   
Risk of high-
grade per 
quartile 
 Q2: 4.7(3.9–
5.5) 
RR=0.29(0.08–
1.06) 
 
Age, BMI, c-
peptide 
   
 
   
Risk of high-
grade per 
quartile 
 Q3: 6.4(5.6–
7.2) 
RR=0.23(0.07–
0.72) 
 
Age, BMI, c-
peptide 
   
 
   
Risk of high-
grade per 
quartile 
 Q4: 8.6(7.3–
10.4) 
RR=0.37(0.12–
1.16) 
 
Age, BMI, c-
peptide 
   
 
   
Risk of high-
grade per 
quartile 
 Q5: 
13.1(10.5–
31.9) 
RR=0.23(0.06–
0.83) 
p=0.08 Age, BMI, c-
peptide 
   
 
Serretta et 
al 2018 
(27) 
Case-
control 
Not stated  Risk of 
Gleason score 
4 and 5 
ELISA Median (25th-
75th 
percentile): 
Low-grade 
1.66(1.52-
1.95), high-
grade 
1.73(1.55-
2.04), p=0.68.  
Not provided  BMI Not 
stated 
68 81 Not stated 
Sher et al 
2008(37) 
Nested 
case-
control 
USA Risk of high-
grade at 
biopsy 
ELISA Dichotomised 
at Median, 
Low ≥12.3 
OR=0.98(0.70-
1.37) 
Wald p=0.899 None Not 
stated 
9 98 Intermediate-
grade 
   
Risk of high-
grade at 
biopsy 
 Dichotomised 
at Median, 
Low ≥12.3 
OR=0.90(0.62-
1.31) 
Wald p=0.581 BMI, prostate 
size 
   
 
   
Risk of high-
grade at RP 
 Dichotomised 
at Median, 
Low ≥12.3 
OR=2.04(1.16-
3.58) 
Wald p=0.014 None    
 
   
Risk of high-
grade at RP 
 Dichotomised 
at Median, 
Low ≥12.3 
OR= 2.14(1.13–
4.07) 
Wald p=0.020 BMI, prostate 
size 
   
 
   
Risk of high-
grade per 
quartile at 
biopsy 
 Q4: >18 Reference 
  
   
 
   
Risk of high-
grade per 
quartile at 
biopsy 
 Q3: 12.3 - 
18.1 
OR=1.25(0.77-
2.02) 
 
None 
 
   
 
   
Risk of high-
grade per 
quartile at 
biopsy 
 Q2: 7.4 - 12.3 OR=1.21(0.75-
1.96) 
 
None    
 
   
Risk of high-
grade per 
 Q1: ≤7.4 OR=0.98 (0.61-
1.59) 
Wald p=0.662 None    
 
quartile at 
biopsy    
Risk of high-
grade per 
quartile at 
biopsy 
 Q3: 12.3 - 
18.1 
OR=1.35(0.80-
2.27 
 
BMI, prostate 
size 
   
 
   
Risk of high-
grade per 
quartile at 
biopsy 
 Q2: 7.4 - 12.3 OR=1.23(0.72-
2.10) 
 
BMI, prostate 
size 
   
 
   
Risk of high-
grade per 
quartile at 
biopsy 
 Q1: ≤7.4 OR=0.90(0.53-
1.55) 
Wald p=0.388 BMI, prostate 
size 
   
 
   
Risk of high-
grade per 
quartile at RP 
 Q3: 12.3 - 
18.1 
OR=1.15(0.52-
2.54) 
 
None    
 
   
Risk of high-
grade per 
quartile at RP 
 Q2: 7.4 - 12.3 OR=2.46(1.13-
5.34) 
 
None    
 
   
Risk of high-
grade per 
quartile at RP 
 Q1: ≤7.4 OR=1.87(0.82-
4.23) 
Wald p=0.085 None    
 
   
Risk of high-
grade per 
quartile at RP 
 Q3: 12.3 - 
18.1 
OR=1.04(0.42-
2.54) 
 
BMI, prostate 
size 
   
 
   
Risk of high-
grade per 
quartile at RP 
 Q2: 7.4 - 12.3 OR= 2.52(1.04-
6.10) 
 
BMI, prostate 
size 
   
 
   
Risk of high-
grade per 
quartile at RP 
 Q1: ≤7.4 OR=1.82(0.72-
4.63) 
Wald p=0.115 BMI, prostate 
size 
   
 
Tewari et 
al 
2013(20) 
Case-
control 
India Risk of high-
grade 
Not stated Increased 
adiponectin 
(increment not 
specified) 
OR=0.86(0.80-
0.92)  
 
None Not 
stated 
62 33 Not stated 
 
Table 6. Extracted data from studies analysing serum adiponectin levels and the incidence of high-grade PCa. C-C: cases vs. controls; SD: standard deviation; SEM: standard error of the mean; 
OR: Odd’s ratio; BMI: body mass index; RR: risk ratio; T: tertile; Q: quartile or quintile; RP: radical prostatectomy. *As presented in tables 1 and 2, respectively. 
 
Study Country Study 
design 
Exposure 
category 
Detection 
assay 
Exposure 
metric  
Risk 
estimate 
Matched 
factors/ 
covariates 
Fasted 
blood 
Cases N Cancer-free 
controls N 
Hormaechea-
Agulla et al 
2017(38) 
Spain Case-control Comparison of 
C-C median 
levels 
ELISA (total 
ghrelin), RIA 
(In1 ghrelin) 
No significant 
difference in levels 
of native ghrelin.  
Significantly 
higher median In1 
Not provided BMI Not stated 30 20 
ghrelin in PCa 
cases (controls 
median 0pg/mL 
(IQR 0–0), cases 
median 4.6pg/mL 
(IQR 0–18), 
p=0.003) 
Malendowicz et 
al 2009(39) 
Poland Case-control Comparison of 
C-C mean 
levels 
RIA Controls mean 
19pg/ml (SEM±5), 
Cases mean 
40pg/ml(SEM±7). 
P-value not 
provided, 
described as 
"significantly 
higher" in text.  
Not provided Not provided Yes 18 16 
 
Table 7. Extracted data from studies analysing serum ghrelin levels and the incidence PCa. C-C: cases vs. controls; SEM: standard error of the mean, In1 ghrelin: oncogenic ghrelin splice variant 
with retention of intron 1, IQR: interquartile range.  
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 Supplementary appendix 1. Search strategies.  
The “no reviews” limit was applied to all databases except PubMed, from which relevant reviews were collected 
to identify further studies from the reference lists. MeSH terms were included in the search strategy in PubMed, 
and exploded EMTREE terms included in the EMBASE search strategy. The “no reviews” limit was applied to 
all databases except PubMed, from which relevant reviews were collected to identify further studies from the 
reference lists. 
 
Pubmed/MEDLINE: 
((prostat* cancer) OR (prostat* neoplasm) OR (prostat* carcinoma) OR (prostat* tumo*)) AND (leptin OR 
adiponectin OR ghrelin) 
 
EMBASE:  
 
'prostate cancer'/exp OR 'prostate cancer' OR 'prostatic neoplasia'/exp OR 'prostatic neoplasia' OR 'prostatic 
neoplasms'/exp OR 'prostatic neoplasms' OR 'prostate carcinoma'/exp OR 'prostate carcinoma' OR 'prostatic 
carcinoma'/exp OR 'prostatic carcinoma' OR 'prostate tumor'/exp OR 'prostate tumor' AND ('leptin' OR 
'leptin'/exp OR leptin OR 'adiponectin' OR 'adiponectin'/exp OR adiponectin OR 'ghrelin' OR 'ghrelin'/exp OR 
ghrelin) NOT ‘review’ 
 
Web of Science (no review filter): 
((prostate cancer) OR (prostate tumor) OR (prostate carcinoma) OR (prostate neoplasm)) AND (ghrelin OR 
leptin OR adiponectin)  
 
Cochrane Library Central Records (Trials) (Trials but not review filters): 
 
("prostate cancer" OR "prostate neoplasm" OR "prostatic neoplasm" OR "prostate tumor" OR "prostate 
carcinoma") AND ("leptin" OR "ghrelin" OR "adiponectin") 
 
 
